






# Integrated care for optimizing the management of stroke and associated heart disease: a position paper of the European Society of Cardiology Council on Stroke

Gregory Y. H. Lip <sup>1,2,3,4,\*†</sup>, Deirdre A. Lane<sup>1,2</sup>, Radosław Lenarczyk<sup>3</sup>, Giuseppe Boriani <sup>5</sup>, Wolfram Doehner <sup>6</sup>, Laura A. Benjamin<sup>7</sup>, Marc Fisher<sup>8</sup>, Deborah Lowe<sup>9</sup>, Ralph L. Sacco<sup>10</sup>, Renate Schnabel<sup>11</sup>, Caroline Watkins<sup>12</sup>, George Ntaios <sup>13</sup>, and Tatjana Potpara <sup>4,14†</sup>

<sup>1</sup>Liverpool Centre for Cardiovascular Science, University of Liverpool and Liverpool Heart & Chest Hospital, Liverpool, UK; <sup>2</sup>Department of Clinical Medicine, Aalborg University, Aalborg, Denmark; <sup>3</sup>Division of Medical Sciences in Zabrze, Department of Cardiology, Congenital Heart Diseases and Electrotherapy, The Medical University of Silesia, Silesian Center of Heart Diseases, Curie-Skłodowska Str 9, 41-800 Zabrze, Poland; <sup>4</sup>School of Medicine, Belgrade University, Belgrade, Serbia; <sup>5</sup>Cardiology Division, Department of Biomedical, Metabolic and Neural Sciences, University of Modena and Reggio Emilia, Policlinico di Modena, Modena, Italy; <sup>6</sup>BIH Center for Regenerative Therapies (BCRT) and Department of Internal Medicine and Cardiology (Virchow Klinikum), German Centre for Cardiovascular Research (DZHK) partner site Berlin and Center for Stroke Research Berlin, Charité Universitätsmedizin Berlin, Berlin, Germany; <sup>7</sup>Laboratory of Molecular and Cell Biology, University College London National Hospital for Neurology and Neurosurgery, Queen Square, London; <sup>8</sup>Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA; <sup>9</sup>Wirral University Teaching Hospital NHS Foundation Trust, Wirral CH49 5PE, UK; <sup>10</sup>UM Clinical & Translational Science Institute, University of Miami, Miller School of Medicine, Miami, FL, USA; <sup>11</sup>University Heart & Vascular Center Hamburg Eppendorf, German Center for Cardiovascular Research (DZHK) partner site Hamburg/Kiel/Lübeck, Hamburg, Germany; <sup>12</sup>Faculty of Health and Care, University of Central Lancashire, Preston PR1 2HE, UK; <sup>13</sup>Department of Internal Medicine, School of Health Sciences, Faculty of Medicine, University of Thessaly, Larissa, Greece; and <sup>14</sup>Cardiology Clinic, Clinical Centre of Serbia, Belgrade, Serbia

Received 17 December 2021; revised 11 March 2022; accepted 27 April 2022


\* Corresponding author. Email: [gregory.lip@liverpool.ac.uk](mailto:gregory.lip@liverpool.ac.uk)

† These authors are co-chairs of the task force.

© The Author(s) 2022. Published by Oxford University Press on behalf of European Society of Cardiology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (<https://creativecommons.org/licenses/by-nc/4.0/>), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact [journals.permissions@oup.com](mailto:journals.permissions@oup.com)

## Graphical Abstract



Integrated care for optimizing the management of stroke and associated heart disease: the post-stroke ABC pathway.

## Abstract

The management of patients with stroke is often multidisciplinary, involving various specialties and healthcare professionals. Given the common shared risk factors for stroke and cardiovascular disease, input may also be required from the cardiovascular teams, as well as patient caregivers and next-of-kin. Ultimately, the patient is central to all this, requiring a coordinated and uniform approach to the priorities of post-stroke management, which can be consistently implemented by different multidisciplinary healthcare professionals, as part of the patient 'journey' or 'patient pathway,' supported by appropriate education and tele-medicine approaches. All these aspects would ultimately aid delivery of care and improve patient (and caregiver) engagement and empowerment. Given the need to address the multidisciplinary approach to holistic or integrated care of patients with heart disease and stroke, the European Society of Cardiology Council on Stroke convened a Task Force, with the remit to propose a consensus on Integrated care management for optimizing the management of stroke and associated heart disease. The present position paper summarizes the available evidence and proposes consensus statements that may help to define evidence gaps and simple practical approaches to assist in everyday clinical practice. A post-stroke ABC pathway is proposed, as a more holistic approach to integrated stroke care, would include three pillars of management:

- A: Appropriate Antithrombotic therapy.
- B: Better functional and psychological status.
- C: Cardiovascular risk factors and Comorbidity optimization (including lifestyle changes).

## Keywords

Stroke • Heart disease • Integrated care • Delivery of care • Patient pathways

## Introduction

The management of patients with stroke is often multidisciplinary requiring input from stroke specialists (doctors and nurses) as well as from internal medicine, neurology, radiology, emergency medicine, primary care, and rehabilitation team (including physiotherapist, speech, and occupational therapists). Given the common shared risk factors for stroke and cardiovascular disease, input may also

be required from a cardiologist, vascular interventionist, vascular surgeon, and neurosurgeon, as well as nurses, patient caregivers, and next-of-kin. Ultimately, the patient is central to all this, requiring a coordinated and uniform approach to the priorities of post-stroke management, which can be consistently implemented by different multidisciplinary healthcare professionals, as part of the patient 'journey' or 'patient pathway,' supported by appropriate education and tele-medicine approaches. All these aspects would ultimately aid

delivery of care and improve patient (and caregiver) engagement and empowerment.

Given the need to address the multidisciplinary approach to holistic or integrated care of patients with heart disease and stroke, the European Society of Cardiology Council on Stroke convened a Task Force, with the remit to review the published evidence and to propose a consensus on Integrated care management for optimizing the management of stroke and associated heart disease. The present position paper summarizes the available evidence and proposes consensus statements that may help to define evidence gaps and simple practical approaches to assist in everyday clinical practice. Nevertheless, the ultimate judgment regarding care of each individual patient must be made by the healthcare providers and the patient and their family together, considering all the distinct circumstances presented by that patient.

Literature searches were conducted in the following databases: PubMed/MEDLINE and the Cochrane Library (including the Cochrane Database of Systematic Reviews and the Cochrane Controlled Trials Registry). Searches focused on English-language sources and studies in human subjects. Articles related to animal experimentation were only cited when the information was important to understanding pathophysiological concepts pertinent to patient management and comparable data were not available from human studies. Additional information was requested from the authors where necessary.

## Integrated care for stroke—why do we need this, peri- and post-stroke

The co-occurring and inter-linked nature of cardiac and cerebrovascular disease (together termed CVD) requires a combined action plan to prevent, identify, treat, and rehabilitate people. To deliver this requires a multi-faceted action on several fronts, involving both the health and social care workforce. It is axiomatic that increasing the collaboration and integration of the cardiac- and stroke-specialist workforces, within an integrated care service model will ensure effective and efficient. Indeed, there needs to be concerted and co-ordinated action to address the underlying risk factors for CVD, requiring greater investment in, and implementation of, disease prevention and health promotion policies.<sup>1</sup>

The importance of an 'integrated care' approach has been applied to other chronic conditions.<sup>2,3</sup> In patients with atrial fibrillation (AF), which is a common cause for ischaemic stroke (IS), the ABC (Atrial fibrillation Better Care) pathway has been proposed as an integrated care approach with three central pillars: '**A**' Avoid stroke (with Anticoagulants); '**B**' Better symptom management, with patient-centred decisions on rate or rhythm control; and '**C**' Cardiovascular and Comorbidity risk optimization.<sup>2</sup> This provides a streamlined approach to management that is applicable to whether the AF patient is managed by any healthcare professional, either the general practitioner or the hospital-based specialist (whether cardiologist or non-cardiologist), minimizing the possibility of conflicting information from healthcare professionals. Indeed, inconsistent information to patients has been associated with poorer patient adherence with their management plan.<sup>4</sup> An integrated care approach is increasingly recommended in guidelines.<sup>5,6</sup>

The ABC pathway when applied to AF patients has been well-validated in post-hoc analyses of clinical trials, prospective cohort studies and a prospective randomized trial.<sup>7</sup> In a systematic review, AF patients adherent with the ABC pathway showed a lower risk of all-cause death [odds ratio (OR): 0.42, 95% CI 0.31–0.56], cardiovascular death (OR: 0.37, 95% CI 0.23–0.58), stroke (OR: 0.55, 95% CI 0.37–0.82) and major bleeding (OR: 0.69, 95% CI 0.51–0.94).<sup>7</sup> Improved clinical outcomes with ABC pathway adherence are evident, even in clinically complex patients such as those with multimorbidity, polypharmacy, and repeat hospitalizations.<sup>8</sup> In the prospective cluster randomized mobile AF application (mAFA)-II trial,<sup>9</sup> rates of the composite outcome of 'IS/systemic thromboembolism, death, and rehospitalization' were lower with the mAFA intervention plus ABC pathway adherent care compared with usual care [1.9 vs. 6.0%; hazard ratio [HR]: 0.39; 95% CI 0.22 to 0.67;  $P < 0.001$ ]. Dynamic bleeding risk monitoring and follow-up reassessments using hypertension, abnormal renal/liver function, stroke, bleeding history or predisposition, labile international normalized ratio, elderly ( $> 65$  years), drugs/alcohol concomitantly score resulted in lower risks of major bleeding (mAFA vs. usual care, 2.1 vs. 4.3% at one year) and increased total oral anticoagulation usage from 63 to 70%.<sup>10</sup> In the mAFA-II trial long-term extension cohort, the beneficial effects were maintained, with a high adherence ( $>70\%$ ) and persistence ( $>90\%$ ) with the ABC pathway using an App-based intervention.<sup>11</sup>

Between 20 and 30% of all strokes are recurrent strokes.<sup>12</sup> An integrated care approach to stroke care can reduce the likelihood of CVD events, but should they occur, it is vital that evidence-based care pathways are in place, with equitable care available for everyone, at any timepoint. These pathways need to provide seamless, integrated, and individualized care and be delivered by a workforce that have the right knowledge, skills, and behaviours, depending on their role along the pathway. All such efforts then need to undergo rigorous evaluation and adaptation in order to spend healthcare resources efficiently.<sup>13,14</sup>

In the UK, the knowledge and skills for stroke-specific care have been clearly laid out in the Stroke-Specific Education Framework (stroke-education.org.uk), which includes 16 Elements of Care from awareness raising of stroke symptoms, through to end of life care, rehabilitation, and return to work. Whilst these have been developed for stroke specialist and stroke relevant staff, many of the knowledge, skills, and behaviours apply equally to the cardiac workforce and care pathways. The need for such standardized and integrated post stroke programmes and follow-up care after rehabilitation seems evident, but programmes are not widely available.<sup>15</sup> Such programmes will help improve the quality of care, as well as help avoid unnecessary variations in patient care, and in patient outcomes as well. They also inform quality standards and allow benchmarking of services and care against recommended standards. In UK stroke care, the standards have informed the Sentinel Stroke National Audit Package (SSNAP; <https://www.strokeaudit.org>) which has underpinned developments in many aspects of stroke care since its inception as the National Sentinel Audit in 1997. The action plan for stroke in Europe also emphasizes the integrated stroke and secondary prevention care.<sup>16</sup>

Similarly, quality improvements in cardiac and stroke services have been achieved through audit programmes, focussing on cardiac surgery, percutaneous coronary interventions, rhythm management,

heart failure, myocardial ischaemia, and congenital heart disease. Unfortunately, they are often focussed on acute care and less on rehabilitation and secondary prevention. Importantly, many of these domains have commonalities with stroke care. For example, heart rhythm issues such as AF significantly increase the risk of first stroke, and if they remain untreated after an acute event increase the risk of stroke recurrence. Such cardiac diseases not only require acute diagnosis and treatment, but rehabilitation and lifelong management.

Thus, closely linked cardiovascular diseases may have overlapping disease management programmes encompassing the entire chain of care. Overall, it is imperative that as we move forwards with integrated stroke, and integrated cardiac, care, we also consider how cardiac and stroke care can become integrated to provide CVD integrated care. Some preliminary data already suggest improvements in functional status with a multidisciplinary approach to care after stroke.<sup>17</sup>

An integrated care approach used for AF can be applied to stroke, given the shared common cardiovascular risk factors including advancing age, male sex, hypertension, diabetes mellitus (DM), valvular heart disease, heart failure, coronary heart disease, chronic kidney disease, inflammatory disorders, sleep apnoea, and tobacco use.<sup>18</sup> An integrated or holistic management pathway for patients following a stroke, that not only targets the prevention of recurrent stroke, but also improves patient functional status and symptoms, and manages cardiovascular risk factors, comorbidities and lifestyle changes can be proposed; this is the focus of this consensus document.

A post-stroke ABC pathway as a more holistic approach to integrated stroke care would include three pillars of management (*Graphical Abstract*<sup>19</sup>):

- A: Appropriate Antithrombotic therapy.
- B: Better functional and psychological status.
- C: Cardiovascular risk factors and Comorbidity optimization (including lifestyle changes).

This approach expands on a clinical concept proposed in 2021 as 'integrated care for stroke medicine—easy as ABC'.<sup>19</sup>

## A: Appropriate antithrombotic therapy

The 'A' criterion ('Appropriate Antithrombotic therapy') in the post-stroke patient refers to the use of oral anticoagulants (OACs), either as a non-vitamin K antagonist OAC (also called a direct OAC or DOAC) or well-managed vitamin K antagonist (VKA, e.g. warfarin) with a time in therapeutic range  $\geq 70\%$  when AF is present or a VKA, if a prosthetic mechanical heart valve is present. Where there is associated atherosclerotic vascular disease and no AF or mechanical valve present, the appropriate use of antiplatelet therapy is needed. A balance is needed between preventing recurrent ischaemic or thrombotic events and major bleeding,<sup>20,21</sup> which is even more challenging if both AF and vascular disease, whether coronary, carotid, or peripheral artery disease, are present. In such patients (ie. AF with stable vascular disease), anticoagulation monotherapy would suffice as thromboprophylaxis,<sup>22</sup> although many physicians would still prescribe combination therapy, despite the paucity of evidence from large randomized trials. In a systematic review and meta-analysis, for

example, the pooled prevalence of carotid stenosis in AF patients was 12.4% (95% CI 8.7 to 16.0), ranging from 4.4 to 24.3%.<sup>23</sup> In AF patients with coronary artery disease, appropriate antithrombotic therapy management varies according the clinical scenario.<sup>24</sup>

When the AF patient has 'stable vascular disease', the patient should be managed with OAC monotherapy.<sup>25</sup> In the AFIRE trial, combination therapy with OAC plus antiplatelets was associated with worse thromboembolic and bleeding outcomes in AF patients with stable coronary disease.<sup>26</sup> In AF patients presenting with an acute coronary syndrome (ACS), a balance between AF-related stroke prevention which requires OAC and reducing cardiac ischaemia in an ACS presentation which requires antiplatelet therapy needs to be reached; to minimize the risk of stent thrombosis after a percutaneous coronary intervention and the risk of bleeding by the combination of OAC with antiplatelet therapy.<sup>27</sup> In patients with asymptomatic high-grade carotid artery stenosis and AF, carotid endarterectomy is commonly considered<sup>28,29</sup> or, in those less suitable for surgery, carotid artery stenting may be chosen<sup>29</sup> notwithstanding the need for a short course of combined antithrombotic therapy after stenting.<sup>28</sup> While more data are needed to inform optimal antithrombotic management in this setting, a recent nationwide observational evidence suggested that OAC therapy alone could be a default treatment for most of these patients, combined with a short period single antiplatelet therapy in those at high risk of a recurrent vascular event.<sup>30</sup>

In stable atherosclerotic vascular disease patients *without AF* at increased risk of ischaemic events, combination therapy with rivaroxaban 2.5 mg bid and aspirin provides some benefits on CVD events (including on stroke) *even in the absence of associated AF*, but at the risk of more major bleeding. In the cardiovascular outcomes for people using anticoagulation strategies trial,<sup>31</sup> the primary composite outcome [cardiovascular death, stroke, or myocardial infarction (MI)] was lower in the low-dose rivaroxaban-plus-aspirin group compared with the aspirin-alone group (HR 0.76; 95% CI 0.66 to 0.86), at the cost of more major bleeding events (HR 1.70; 95% CI, 1.40 to 2.05). In the rivaroxaban-plus-aspirin group, mortality was also lower (HR 0.82; 95% CI, 0.71 to 0.96), as was IS (HR 0.51; 95% CI 0.38–0.68) compared with the aspirin-alone group.<sup>31</sup>

Proactive mitigation of bleeding risks should be directed at the modifiable bleeding risk factors (uncontrolled blood pressure, reducing alcohol excess, etc.) and scheduling the high bleeding risk patients for early review and follow-up. In the prospective cluster randomized mAFA-II trial of general AF patients, this approach resulted in a reduction in major bleeding at 1 year follow-up and an increase in OAC use.<sup>10</sup>

## Antiplatelet therapy

The standard, and guideline, recommended approach for the use of antiplatelet drugs for secondary stroke prevention for non-cardioembolic stroke has been with aspirin and clopidogrel or ticagrelor.<sup>32</sup> The combination of aspirin and extended-release dipyridamole has also been recommended but has fallen out of favour after the results of the prevention regimen for effectively avoiding second strokes trial demonstrated no difference as compared to clopidogrel for IS outcomes and a significantly higher risk for intracranial haemorrhage and discontinuation because of headaches.<sup>33</sup> The dose of aspirin recommended ranges from 50–325 mgs daily, but most

practitioners use a lower dose given that there is no significant difference in efficacy between lower and higher doses and higher doses are associated with more gastrointestinal side effects.

The combination of aspirin plus clopidogrel or ticagrelor vs. aspirin alone was evaluated in three, large, relatively recent randomized clinical trials. The first was the Clopidogrel in High-Risk Patients with Non-disabling Cerebrovascular Events (CHANCE) that evaluated the combination of clopidogrel plus aspirin for 21 days after a 300 mg loading dose of clopidogrel, followed by clopidogrel monotherapy up to day 90 vs. aspirin alone in a Chinese population with mild stroke [National Institutes of Health Stroke Scale (NIHSS) <3] or high-risk transient ischaemic attack (TIA) with an ABCD2 score  $\geq 4$ .<sup>34</sup> The early combination therapy group had significantly fewer primary outcome events without an increased for major or severe bleeding. Interestingly, in this clinical trial patients with a CYP219C allele, that identified them as a slow metabolizer of clopidogrel to its active prodrug, did not benefit from the combination antiplatelet therapy, while those without it had significantly fewer primary outcome events.<sup>35</sup>

The Platelet-Oriented Inhibition in New TIA and Minor Ischaemic Stroke (POINT) trial evaluated the clopidogrel-aspirin combination vs. aspirin alone in a heterogeneous population of minor stroke (NIHSS <3) and high-risk TIA patients with an ABCD2 score  $\geq 4$ .<sup>36</sup> In the POINT trial patients were given a 600-mg loading dose of clopidogrel followed by 75 mgs daily from day 2 to day 90 plus aspirin vs. aspirin alone. The results demonstrated a significant reduction in the primary outcome of IS, MI and ischaemic vascular death in the combination group, but this was associated with a significantly increased risk of major haemorrhage. In the POINT trial, presence of a clopidogrel slow metabolizer genetic variant was not associated with a significant reduction in efficacy, but there was a trend towards lower efficacy in these patients, although this did not reach significance due to the small sample size.<sup>37</sup> Following the results of these two trials, the combination of aspirin and clopidogrel is now recommended for patients with recent minor (NIHSS score  $\leq 3$ ) noncardioembolic IS or high-risk TIA (ABCD2 score  $\geq 4$ ). It should be started early (ideally within 12–24 h of symptom onset and at least within 7 days of onset) and continued for 21–90 days. Then, it should be followed by single antiplatelet treatment.<sup>38</sup>

A recent trial, The Acute Stroke or Transient Ischaemic Attack Treated with Ticagrelor and ASA for Prevention of Stroke and Death trial (THALES) compared treatment with ticagrelor plus aspirin to aspirin monotherapy for 30 days in patients with a mild to moderate stroke, NIHSS <5 or high-risk TIA with an ABCD2 score  $\geq 6$ .<sup>39</sup> The primary outcome of stroke both ischaemic and haemorrhagic as well as the secondary outcome of IS was significantly reduced in the combination therapy arm. The combination therapy group had an increased risk of severe and intracranial/fatal bleeding. A subgroup analysis of THALES demonstrated that the benefit of the combination therapy only occurred in patients with documented large artery stenosis of 30% or greater and was not associated with an increased risk of bleeding.<sup>40</sup> In the CHANCE-2 trial, among patients with prior stroke/high-risk TIA and CYP2C19 loss-of-function carriers, the use of ticagrelor plus aspirin was associated with significant modest reduction in 90-day risk of subsequent stroke compared with clopidogrel plus aspirin.<sup>41</sup>

The Food and Drug Administration in the United States recently approved the combination of ticagrelor plus aspirin for secondary stroke prevention. In some Asian countries, another drug with antiplatelet activity, cilostazol, is approved for use and widely employed. Indeed, a recent trial in Japan, combining cilostazol with aspirin or clopidogrel, demonstrated that the combination was superior to aspirin or clopidogrel alone without an increased risk for major bleeding.<sup>42</sup> However, cilostazol is not approved for stroke prevention in Europe or the United States.

## **B: Better functional and psychological status—interventions for those with disability, physiotherapy, care packages, etc**

For all stroke patients, whether ischaemic or ICH, whether suitable for hyperacute interventions or not, the focus of care should not only be on limiting the effects of the initial event, but on limiting brain damage as well as preventing complications, and initiating rehabilitation. These are the basis for good quality organized acute stroke care and result in better patient outcomes.<sup>43,44</sup>

The stroke pathway is not straightforward as up to 40% of patients get worse after they come into the stroke unit, mostly within the first 24 h.<sup>45</sup> This is referred to as early neurological deterioration, which, if it persists, is termed stroke progression and reflects secondary brain injury.<sup>46,47</sup> This fluctuation in patient's condition can be the result of potentially reversible physiological or neurological factors (brady-/tachycardia, high or low blood glucose, increased metabolic rate in infection) although sometimes they are irreversible (e.g. mass effect, brain stem herniation).

A goal of holistic post-stroke care is to achieve improved functional and psychological status and, given its multifactorial nature, will require a multidisciplinary approach. There have been incremental gains in terms of interventions delivered by the multi-disciplinary teams and focused on rehabilitation and functional recovery (Supplementary material online, Table S1). Important examples include arm-robot therapy and mirror therapy which reduced motor deficits and electro-mechanical gait training which increased the number of stroke patients that re-gained the ability to walk.<sup>48,49</sup> Similarly, the use of treadmill training helped to improve walking speed and walking endurance among ambulatory stroke survivors.<sup>50,51</sup> However, the absence of standard templates for designing and performing large-scale stroke rehabilitation trials has somewhat limited further progress in the field.<sup>52</sup> In the wake of the digital revolution, telemedicine, virtual reality, and robotics have been tried and tested but are yet to translate to real, measurable functional benefits after a stroke.<sup>52</sup> Innovative approaches that integrate stroke survivors into the exercise portion of an existing hospital-based cardiac rehabilitation programme have shown promise, improving endurance, health status, and quality of life for survivors of stroke and providing an opportunity for self-management.<sup>53</sup>

It is imperative that physiological and neurological monitoring regimes are in place and that any abnormalities are acted on quickly to avoid further secondary brain injury. Furthermore, these patients are

also at risk of the resulting effects of the stroke, as well as the complications of immobility. Care packages and management pathways need then to be put in place immediately and tailored rehabilitation commenced and personalized appropriately to the patient's needs, both in hospital, during rehabilitation and post-discharge.

Indeed, care packages have been developed and evaluated for their effects on outcomes. The most notable is the Quality in Acute Stroke Care,<sup>54</sup> which demonstrated the effectiveness of a care bundle of the assessment and management of Fever, Sugar (hyperglycaemia) and Swallowing dysfunction, in improving outcome by 3 months post-stroke.

Several prognostic tools to predict functional status after stroke have been used.<sup>55–58</sup> Perhaps the most widely employed outcome scale in stroke medicine and research is the modified Rankin Scale, a seven-level, clinician-reported, measure of global disability.<sup>59</sup> Greater functional gain amongst post-stroke survivors during inpatient rehabilitation is associated with better health-related quality of life and independence at follow-up.<sup>60</sup>

Another common complication which develops in approximately one third of stroke survivors is post-stroke depression (PSD) and is associated with unfavourable outcomes after stroke.<sup>61</sup> The frequency of PSD is higher at the first year after stroke, and the main factors contributing to this condition are physical disability, stroke severity, history of depression, and cognitive impairment.<sup>62</sup>

Post-stroke dementia is often under-recognized with a prevalence of approximately 30% among stroke survivors.<sup>63,64</sup> Again, awareness and a multidisciplinary approach is needed, with neuropsychological evaluation adapted to the clinical status.<sup>63,64</sup> The incidence of post-stroke dementia increases with older age, low education status, dependence on others for daily living, pre-stroke cognitive decline without dementia, DM, AF and other cardiac arrhythmias, sepsis, congestive heart failure, silent infarcts, brain atrophy, and leukoaraiosis.

In the long run, stroke survivors and their families and caregivers will encounter several challenges: poor quality-of-life, stroke-related disabilities, inadequate sources of rehabilitation, social isolation and inadequate support of care givers, overburdening and burnout of care givers, and inadequate efforts to maintain normal life and professions.<sup>65–67</sup> To meet up to the expectations of patients and families for a good recovery and proper social re-integration, a patient-centric holistic approach of synergistic integrated care is needed involving a multidisciplinary bundle of health care professionals and related services.

## **‘C’: Cardiovascular risk factors and comorbidities optimization**

Multiple CVD risk factors and comorbidities are common in stroke patients, and part of a multidisciplinary integrated care approach is to address all these risk factors in a holistic manner. This will include management of AF, atherosclerotic vascular disease, systemic hypertension, heart failure, DM, dyslipidaemia, sleep apnoea, and underlying cardiac ischaemia. The ultimate goal is to lower the associated cardiovascular risk burden in these patients, to reduce the risks of recurrent stroke or other major adverse cardiovascular events.

## **Lifestyle changes**

### **Lifestyle changes**

Epidemiological studies have demonstrated that five modifiable risk factors, blood pressure, unhealthy diet, abdominal obesity, physical inactivity, and smoking account for >80% of the population attributable risk for stroke<sup>68,69</sup> and are often poorly managed and controlled post-stroke thus increasing the risk of recurrent stroke.<sup>70</sup> Most strokes are largely preventable with healthy lifestyle choices. Hence, multifactorial lifestyle and behavioural interventions, based on theoretical models of behaviour change, employing established methods, delivered by an interdisciplinary team, are likely to have the greatest cumulative benefit in stroke populations.

### **Diet/nutrition**

There is limited evidence to support dietary interventions to reduce recurrent stroke and the protective effects of nutrition are inferred from epidemiological studies evaluating the effect of dietary factors on risk factors for stroke such as hypertension and hypercholesterolaemia.<sup>71,72</sup> Recommendations on diet and nutrition post-stroke advocate adoption of a Mediterranean-type diet,<sup>71,73–76</sup> with evidence suggesting that high intake of fruit and vegetables,<sup>71,76–81</sup> fibre,<sup>76,78</sup> and regular consumption of fish<sup>71,74,78,82</sup> confers protection against cardiovascular disease, including stroke, whilst diets high in red and processed meats, fried food, eggs, and sugar-sweetened beverages are associated with increased risk of stroke.<sup>71,76,78,80,81</sup> A low-salt diet has been associated with reductions in stroke risk.<sup>72,83–85</sup> Secondary prevention studies,<sup>73,75</sup> one<sup>75</sup> in stroke patients, have demonstrated reductions in IS<sup>75</sup> and death and recurrent MI<sup>73</sup> with Mediterranean-style diets.

### **Obesity**

Weight reduction is recommended for overweight and obese patients with IS or TIA to improve their overall cardiovascular risk profile, with referral to multifactorial intensive lifestyle interventions for obese individuals.<sup>38</sup> Evidence, predominantly from obese patients with diabetes, demonstrates that a 5–10% weight loss, either through traditional behavioural intervention programmes,<sup>86</sup> food substitution,<sup>87</sup> or bariatric surgery,<sup>88</sup> can improve conventional cardiovascular risk factors, namely blood pressure, hyperglycaemia, and dyslipidaemia. Comprehensive behavioural programmes incorporating counselling as a key component appear most effective, with sustained weight loss.<sup>89,90</sup> There are no clinical trials demonstrating that weight loss reduces recurrent stroke in an acute IS population, but observational data post-bariatric surgery suggests some benefit of weight reduction on stroke risk (Supplementary material online, Table S2).<sup>91</sup>

### **Physical activity**

Exercise and regular physical activity reduce the risk of stroke<sup>80,92,93</sup> and positively impact stroke risk factors by reducing weight<sup>94</sup> and lowering blood pressure (BP) and cholesterol.<sup>93,95,96</sup> Patients should be encouraged to resume physical activity, with supervision and support as required. Where able, survivors of stroke should participate in 40 min of moderate-vigorous intensity aerobic activity, three to four times per week, otherwise physical activity should be individualized, commensurate with their level of exercise tolerance, stage of

recovery, environment, available social support, physical activity preferences, and specific impairments.<sup>38,97</sup>

Systematic reviews of lifestyle-based interventions<sup>95,98,99</sup> and exercise-only interventions<sup>95</sup> for secondary stroke prevention are effective in reducing cardiovascular risk factors but their impact on mortality, recurrent stroke, and other vascular events remains to be determined.<sup>98,99</sup> Most stroke patients are sedentary and available studies are in TIA patients and ambulatory stroke patients. A post-hoc analysis of the Stenting and Aggressive Medical Management for Preventing Recurrent Stroke in Intracranial Stenosis study<sup>80</sup> of those assigned to aggressive medical therapy and targeted risk factor management demonstrated that greater physical activity was associated with lower risk of recurrent stroke, MI or death (OR 0.6, 95% CI 0.4–0.8) and recurrent IS alone (Supplementary material online, Table S2).

### Alcohol consumption

High levels of alcohol consumption (women: >3 drinks/day or >7 drinks/week; men: >4 drinks/day or >14 drinks/week) are associated with greater risk of stroke<sup>100</sup> and are an independent risk factor for stroke recurrence.<sup>101</sup> Low-to-moderate alcohol intake appears to be protective but risk of IS increases (HR 1.04, 95% CI 1.02–1.07) with every 12 g/d increase in alcohol consumption.<sup>102</sup> There are no intervention studies that have directly examined the effect on reducing alcohol intake on risk of recurrent stroke. One small secondary stroke prevention trial focused on lifestyle modification<sup>103</sup> demonstrated reduced alcohol intake but the direct effect on the risk of recurrent stroke could not be determined.

### Smoking cessation

Cessation of smoking post-stroke is an essential health behaviour to promote and support secondary prevention; patients should be offered counselling with or without pharmacological intervention (nicotine replacement/medication).<sup>13,103,104</sup> Up to two thirds of stroke survivors continue to smoke,<sup>105</sup> thus increasing the risk of recurrent stroke approximately two-fold compared to non-smokers;<sup>106</sup> the more smoked the greater the risk.<sup>106</sup> If a person cannot stop smoking, they should be encouraged to reduce daily smoking<sup>105,106</sup> and limit passive smoking.<sup>107</sup>

No randomized controlled trials (RCTs) have demonstrated a significant reduction in recurrent stroke following a smoking cessation intervention. One multifactorial RCT<sup>13</sup> employing motivational interviewing targeting modifiable risk factors (smoking, hypertension, diabetes, AF) in patients with a recent ( $\leq 2$  weeks) non-disabling stroke or TIA, demonstrated a significant impact of the intervention on smoking cessation but no difference between intervention and control groups on major vascular events over an average 3.6 years of follow-up (Supplementary material online, Table S2).

### Finding AF

AF is responsible for 17–36% of ISs, and in up to one-quarter of patients, IS or TIA is a first manifestation of AF. AF-related strokes more commonly lead to death or are disabling, compared to other aetiologies.<sup>108,109</sup> An active search for AF is imperative in patients with IS of unknown origin, as detection of arrhythmia and the initiation of OAC may protect the patient against another IS. AF detection rate depends not only on patient characteristics, the time since

the stroke, type of stroke, and adopted definition of AF but also on monitoring duration and quality (Supplementary material online, Table S3). As a general principle, if we 'look harder, look longer and look in more sophisticated ways ....', we are more likely to find more AF in our post-stroke patients.

Currently, the recommended approach in post-stroke patients without known AF mandates screening for the arrhythmia with short-term 24 h continuous electrocardiogram (ECG) monitoring, followed by prolonged ( $\geq 72$  h) ECG monitoring. As shown by analysis of the LOOP study (Atrial Fibrillation Detected by Continuous ECG Monitoring Using Implantable Loop Recorder to Prevent Stroke in High-risk Individuals), single 72 h ECG monitoring yields sensitivity of only 15% in detecting AF,<sup>110</sup> and the 2018 Canadian Stroke Best Practice Recommendations advocate  $\geq 2$  weeks ECG monitoring in patients with ESUS.<sup>111</sup>


To date, the optimal duration and method of ECG screening remain elusive and requires further research. Implantable cardiac monitors, by providing continuous monitoring, offer the capability to maximize the chances to detect AF and should be considered after non-invasive monitoring of 7–14 days, up to 30 days in patients with previous stroke at higher probability of having AF (Figure 1). In the LOOP study, performed in patients 'at risk' aged  $\geq 70$  years but not limited to patients with previous stroke, the combination of slower resting sinus rate, higher body mass index, NT-pro BNP, troponin T together with sex, age, and comorbidities, improved prediction of AF episodes  $\geq 24$  h duration.<sup>110</sup>

Recently, new screening tools, based on a single-lead ECG or a pulse wave (detected e.g. with plethysmography or oscillometric blood pressure), have emerged, but the clinical utility of majority has yet to be proven, especially in post-stroke patient.<sup>123,124</sup> On the other hand, new hand-held or worn (belts, patches, smartphone apps) single-ECG recorders demonstrate good sensitivity and specificity.<sup>125</sup> A recent multicentre RCT in patients with IS or transient ischaemic attack (TIA) demonstrated that 30-day smartphone-based ECG monitoring was better than one additional 24 h Holter monitoring in detecting  $\geq 30$ s AF (9.5 vs. 2.0%;  $P=0.024$ ) and led to more frequent OAC use at 3 months (9.5 vs. 0%,  $P=0.002$ ).<sup>115</sup>

In summary, a considerable burden of previously unknown AF can be detected when long-term monitoring is applied in at-risk patients.

## Hypertension, DM, hypercholesterolaemia Blood pressure

Hypertension is the most prevalent and modifiable risk factor for primary prevention of stroke. Most studies have also shown that control of BP is beneficial for prevention of a recurrent stroke—Supplementary material online, Table S4.<sup>32,127</sup> The management of blood pressure in the acute phase of a stroke is more variable and depends on whether thrombolysis is administered for IS. Guidelines call for reducing systolic blood pressure (SBP) below 185 mmHg and diastolic below 110 mmHg before IV thrombolysis is started.<sup>128</sup> Given the urgency of reperfusion initiation, IV BP treatments with agents such as labetalol or nicardipine are warranted with close interval BP monitoring after thrombolysis in the first 24 h and maintaining BP of less than 185/105 mmHg. Although intracerebral hemorrhage was reduced, intensive BP lowering after IV



**Figure 1** Proposed approach to screening for atrial fibrillation in post-stroke patients. AF, atrial fibrillation; CAD, coronary artery disease; PM, pacemaker; ICD, implantable defibrillator-cardioverter; PAC, premature atrial complexes; LA, left atrium; TVR, tricuspid valve regurgitation; MVR, mitral valve regurgitation; NT-proBNP, N-terminal pro-brain natriuretic peptide; BNP, brain natriuretic peptide; HR, hazard ratio; OR, odds ratio; ICM, implantable cardiac monitor; ESUS, embolic stroke of undetermined source. \*PR interval (per 10 ms) off PR prolonging drugs; HR 1.58 (95% CI 1.32–1.90) for AF in 12 months; HR 1.41 (95% CI 1.21–1.64) for AF in 36 months PR interval (per 10 ms) on PR prolonging drugs; HR 1.17 (95% CI 1.02–1.35) for AF in 12 months; HR 1.15 (95% CI 1.01–1.30) for AF in 36 months.<sup>112</sup> Other ECG markers of atrial myocardiopathy (such as P wave dispersion, P wave index, maximum P-wave duration) could be useful in predicting AF in specific subgroups of patients high-risk for AF.<sup>113</sup> \*\*Age (per 10 years) HR 1.91 (95% CI 1.31–2.80) for AF in 12 months; HR 1.84 (95% CI 1.33–2.52) for AF in 36 months.<sup>112</sup> #PAC >123/24 h; HR 3.94 (95% CI 1.30–11.97) for AF in 12 months; HR 3.41 (95% CI 1.38–8.70) for AF in 36 months—univariate analysis.<sup>112</sup> Greater than or equal to 30 PAC per hour or any episode of runs of  $\geq 20$  PACs; HR 2.37 (95% CI 1.07–6.96) for AF in 36 months.<sup>114</sup> \$LA size >45 mm; HR 3.6 (95% CI 1.6–8.4) for AF within 1 year.<sup>115</sup> @Odds ratio for cardioembolic stroke for highest quartile of BNP in clinical + BNP model OR 4.49 (95% CI 3.26–6.2); for lowest quartile of BNP in clinical + BNP model OR 7.1 (95% CI 4.98–10.12); for highest quartile of NT-proBNP in clinical + NT-proBNP model OR 6.17 (95% CI 4.31–8.84); for lowest quartile of NT-proBNP in clinical + NT-proBNP model OR 3.34 (2.44–4.59).<sup>116</sup> \$\$C<sub>2</sub>HES<sub>2</sub> score [CAD/COPD (1 point each), Hypertension (1 point), Elderly ( $\geq 75$  years, 2 points), Systolic heart failure (2 points), and Thyroid disease (hyperthyroidism, 1 point)].<sup>117</sup> The risk of AF increases with increasing score values, being the highest in patients with a C<sub>2</sub>HES<sub>2</sub> score of  $>3$ .<sup>117</sup> ##Hazard ratios for post-stroke AF based on references.<sup>112,114–116,118–122</sup>

thrombolysis to SBP of 130–140 mm Hg has not been shown to improve 90-day functional outcomes compared to target SBP of  $<180$  mm Hg.<sup>129</sup>


The management of BP after endovascular thrombectomy (EVT) is also unclear. Most acute EVT trials for acute IS excluded patients if BP was greater than 185/110 mmHg. The recent blood pressure lowering after successful endovascular therapy in acute ischaemic stroke trial failed to show any significant difference in radiographically determined intraparenchymal haemorrhage risks for intensive BP control (100–129 mmHg) compared to standard (SBP 130–185 mmHg) among successfully EVT treated large vessel occlusion cases.<sup>130</sup> Ongoing trials (for example, BEST-II: NCT04116112, OPTIMAL\_BP: NCT04205305, ENCHANTED 2: NCT04140110, CRISIS I: NCT04775147) are continuing to address whether more intensive BP management is better than standard SBP targets of  $<180$  mmHg after successful reperfusion.

After the acute stroke period, management and control of BP with targets of  $<140/90$  mmHg to reduce stroke recurrence and other cardiovascular conditions are supported in evidence-based recommendations.<sup>32</sup> Among diabetics and those with cerebral small vessel disease, more aggressive targets of  $<130/80$  mmHg are reasonable.

For intracerebral haemorrhagic strokes, rapid or intensive lowering of SBP to  $<180$  mmHg did not improve functional outcomes at 90 days.<sup>131–133</sup> Overall, there is insufficient evidence to show that lowering BP reduces haematoma expansion. In combined analyses among the subgroup of patients treated within 6 h, intensive BP lowering ( $<140$  and  $>110$  mmHg) has been recommended based on the lower risk of haematoma expansion.<sup>134</sup>

In summary, sudden and significant reduction of blood pressure during acute phase of ischaemic or haemorrhagic stroke may worsen outcomes; however, after acute period, tight BP control ( $<140/$





**Figure 2** Proposed management in patient with diabetes mellitus and stroke. Patients with post-stroke hyperglycaemia and hypoglycaemia are at a high risk of cardiovascular complications and blood glucose should be proactively managed. ASCVD, atherosclerotic cardiovascular disease; CAD, coronary artery disease; CKD, chronic kidney disease; DW25, dextrose 25% in water; DW50, dextrose 50% in water; DM, diabetes mellitus; GLP-1RA, glucagon-like peptide-1 receptor antagonist; HF, heart failure; HbA1c, glycated haemoglobin; FPG, fasting plasma glucose; PAD, peripheral artery disease; PPG, postprandial glucose; TBR, time below range, TIR, time in range; SGLT2i, sodium glucose co-transporter-2 inhibitor.

90 mmHg, or <math>< 130/80</math> mmHg in diabetics) protects against recurrent stroke and other cardiovascular events.

### Diabetes mellitus


All stroke patients without diagnosed diabetes should be screened for DM. Despite unfavourable effects of hyperglycaemia in acute IS in diabetic, and non-diabetic patients,<sup>135–137</sup> as showed by many studies (Supplementary material online, Table S5), strict glycaemia control (e.g. 70–135 mg/dL) in acute stroke is not beneficial and may be even harmful, putting the patient at risk for hypoglycaemia and early neurologic deterioration.<sup>138–140</sup> Thus, the accepted approach to glycaemia in acute stroke is less stringent (e.g. range 70–180 mg/dL).<sup>128,141</sup> Patients with post-stroke DM are at a very high risk of cardiovascular complications and should be tightly controlled with a target glycosylated haemoglobin 1c <math>< 7\%</math> (see Figure 2 for proposed management).<sup>142,143</sup>

In summary, while less stringent glycaemia control is beneficial in the acute phase of stroke, post-stroke patients should be subjected to rigorous, long-term glycaemic control.

### Dyslipidaemia

The available evidence on role of dyslipidaemia for pathogenesis of stroke is moderately robust, but most of the data (Supplementary material online, Table S6) indicate that lowering LDL-C is the primary target in IS, and each 1 mmol/L (39 mg/dL) decrease in LDL-C levels reduces the risk of any stroke by 21.1%.<sup>144</sup> First-line drugs are statins.

In patients with initial LDL-C levels which are much higher than the target LDL-levels, ezetimibe could be started right away as an add-on treatment to statins. Although the related evidence is low, especially when compared to the role of immediate onset of statin treatment in patients with acute MI, we suggest that statins with or without ezetimibe is instituted early in the acute phase, as this strategy reduced risk of recurrent stroke in TIA patients with carotid stenosis.<sup>145</sup> Long-term statin use reduced reoccurrence of fatal or non-fatal stroke in patients after stroke or TIA (in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels study HR 0.84; 95% CI 0.71–0.99), and higher statin adherence reduced risk of recurrent stroke in patients with recent IS without AF (HR 0.78; 95% CI, 0.63–0.97) and with AF (HR 0.59; 95% CI, 0.43–0.81).<sup>146,147</sup> Initial reports had generated the hypothesis that statins and other lipid-lowering drugs may perhaps increase the of haemorrhagic stroke, but this was not confirmed in plenty of large-scale epidemiological studies.<sup>148,149</sup> Patients with IS are at very high cardiovascular risk and should be subject to at least 50% reduction of LDL-C with target LDL-C value of 1.4 mmol/L (55 mg/dL).<sup>150–152</sup> Patients with IS or TIA which is attributed to a specific aetiology that is not related to cardiovascular risk factors like cervical artery dissection, patent foramen ovale (PFO), endocarditis, and atrial myxoma should not be a priori considered as of very high risk for stroke recurrence and cardiovascular morbidity and mortality. For such patients, it is suggested that lipid lowering treatment should be based on a personalized 10-year cardiovascular risk, estimated by the calibrated country-



**Figure 3** Proposed management of dyslipidaemia in ischaemic stroke. PCSK9-i, proprotein convertase subtilisin/kexin type 9 inhibitor.

**Table 1** A summary of potential stroke aetiologies and how to test for them

Stroke aetiology	Testing approach
Large artery disease	CT or MR angiography
Small vessel disease	Brain MRI—evaluate the topography of the infarct
Structural cardiac abnormality	Transthoracic and/or transesophageal echocardiogram, bubble test
Cardiac arrhythmia	Prolonged ECG monitoring: at least 14–28 days
Plaque of the ascending aorta	Transesophageal echocardiogram
Hypercoagulable state	Hypercoagulable blood testing
Lower extremity deep vein thrombosis	Lower extremity ultrasound or MR veinogram

specific SCORE.<sup>153</sup> Figure 3 shows the proposed management of dyslipidaemia in IS.

In summary, LDL-C lowering is the primary target in IS and an early institution of statins and their long-term use reduce the risk of a recurrent stroke.

In patients at increased risk of ischaemic events owing to elevated triglyceride levels despite statin use the additional triglyceride-lowering therapy reduces the residual risk and improve survival.<sup>154</sup>

## Other comorbidities

### Patent foramen ovale

PFO is a common abnormality that affects up to 20–25% of women and a smaller percentage of men.<sup>155</sup> In most people, a PFO remains asymptomatic, but in a small percentage, it may be associated with the development of an embolic IS via paradoxical embolization. Before concluding that a PFO is the causative mechanism for an IS, an exhaustive search for other stroke aetiologies should be performed (Table 1).

When other potential stroke aetiologies have been excluded and the PFO is determined to be the likely stroke mechanism, then treatment options to prevent future strokes need consideration. The risk of a recurrent stroke in PFO-related stroke is low, approximately 1–2% per year, but it is more substantial in higher risk PFOs, i.e. those with a larger amount of intracardiac shunting or when the PFO is associated with an atrial septal aneurysm.<sup>156</sup>

Two approaches to secondary prevention are employed: antithrombotic therapy that in most cases consists of antiplatelet treatment or alternatively interventional closure of the PFO by occluder or remote surgical (stitch) technology. These two therapeutic approaches were evaluated in clinical trials in PFO-related stroke patients under the age of 60<sup>157</sup> as it is understood that with higher age other potential causes of stroke may be increasingly prevalent even if they had not been detected in standard diagnostic workup. In these patients it was demonstrated that PFO closure with long term antiplatelet therapy was superior to medical therapy alone, but the benefit was only observed in patients with high-risk PFOs (i.e. long-tunnel PFO ≥ 10 mm, hypermobile interatrial septum, Eustachian valve or Chiari’s network, a large right-to-left shunt during Valsalva manoeuvre, low-angle PFO ≤ 10°). PFO closure was

associated with a risk of developing transient AF, as well an increased incidence of haematomas, deep vein thrombosis, and pulmonary embolism.<sup>158</sup> The increased risk of postprocedural AF declines after the early postprocedural period (e.g. first 45 days after PFO closure) but remains elevated compared with the general population during a long-term follow-up.<sup>159</sup>

The evaluation of patients with presumed PFO-related ISs requires close collaboration between stroke specialists and imaging and interventional cardiologists.<sup>160</sup> The stroke specialist should determine if the stroke was likely embolic and perform appropriate evaluation to exclude other potential stroke mechanisms, such as large and small artery atherosclerosis and other potential cardiac sources, whilst the cardiologist can assist in performing and interpreting cardiac imaging to identify a cardiac source of the stroke. This should be followed by multidisciplinary team (MDT) discussion about the best approach for secondary stroke prevention. An MDT meeting should be mandated for patient evaluation and selection of intervention.

### Cardiac thrombus

In patients with an acute stroke in whom a cardio-embolic mechanism is suspected the following potential causes should be excluded: AF or flutter, thrombi in the left ventricle (LV) or in the left atrium/left atrial appendage, or on a prosthetic cardiac valve, as well as other conditions such as mitral stenosis, atrial myxoma, intracardiac masses, or valvular vegetations.<sup>161</sup>

LV mural thrombi account for up to 10% of cardio-embolic strokes and are most often seen in patients who have had a prior extensive anterior MI, with segmental akinesis or dyskinesis.<sup>162–164</sup> Usually, the development of a LV thrombus occurs between 24 h and 2 weeks after the onset of a MI, with an increased risk in patients with depressed LV function.<sup>162</sup> The risk of stroke or systemic embolism in the absence of anticoagulation, is as high as 10–20% at 3 months, with the highest risk in the first weeks,<sup>163,164</sup> declining after 3 months, in parallel with evolution to an organized and fibrotic clot adhering to the endocardium.

Transthoracic echocardiography (TTE) is traditionally the standard imaging technique for detecting LV thrombi in patients with acute IS.<sup>161</sup> More recently, cardiac magnetic resonance (CMR) was found to be superior to TTE in detecting LV thrombus in patients with history of MI and LV dysfunction (LVEF < 50%), with cine-CMR and contrast-enhanced CMR offering the highest diagnostic yield, especially in case of mural or small LV thrombi.<sup>165–168</sup> Since CMR is a time-consuming, expensive examination, not easily available in most centres, new approaches have been developed in the field of echocardiography, with ultrasound contrast agents significantly improving the diagnostic accuracy of TTE.<sup>168</sup>

Anticoagulation is absolutely indicated if a LV thrombus is detected and has to be integrated and combined with control of hypertension and other risk factors. For oral anticoagulation, VKAs have been traditionally recommended. For the DOACs, few data are available, limited to case reports and case series, and their use in this setting remains off-label.<sup>168–170</sup>

## MDTs and the roadmap to potentiate integrated stroke care

There are multiple pathologies that may lead to an IS: diseases of the arteries and diseases of the heart, thrombosis-mediated and


thrombosis-unrelated, embolic and small-vessel disease, atherosclerotic, and non-atherosclerotic (Figure 3). The myriad of cardiac, vascular, haematologic, and other underlying aetiologies highlights that stroke is not caused by a single disease.<sup>171</sup> Moreover, many prevalent cardiovascular comorbidities are risk factors for these pathways leading to stroke such as arterial hypertension, DM, dyslipidaemia, heart failure, smoking, obesity, and physical inactivity to name only the most prevalent.<sup>69</sup> Hence, engaging in the prevention of a first or recurrent stroke is a challenging task that requires competency in the management of the complex interactions outlined above.

To add further to the complexity of integrated care for stroke, there are many challenges when treating a patient with acute and subacute ischaemic or hemorrhagic stroke. Although only a minority of stroke patients arrive rapidly enough to hospital settings, timely recanalization of an occluded cerebral artery is crucial as it may markedly improve patient outcomes, especially for those patients treated with endovascular treatment, with one of the best number-needed-to-treat metrics in medicine.<sup>172</sup> Recanalization treatments have advanced in recent years from the technically-simple intravenous administration of alteplase in the early 90 s to the modern innovative interventional endovascular procedures which are further enhanced by sophisticated imaging and artificial intelligence.

Most stroke patients develop several typical complications of cardiovascular, infectious, metabolic, neurologic, and neurosurgical nature, which need to be handled in a holistic multi-system approach. Such treatment is best provided on specialized stroke units (indeed, the Action Plan for Stroke in Europe 2018–2030 targets to treat 90% or more of all patients with stroke in Europe in a dedicated stroke unit as the first level of care<sup>16</sup>) and the interdisciplinary care concepts of close monitoring and early treatment of multiple complications are the key principle of stroke unit care—treating not the stroke, but the patients with stroke. Simultaneously, the diagnostic quest for the underlying cause occurs in parallel with acute stroke management and incorporates sophisticated multimodal diagnostic tools that add to the complexity by bringing up puzzling diagnostic challenges and uncertainties.<sup>173–175</sup> Clearly, a MDT is required to contribute specialized expertise from a range of specialties involved as individually required.

It is evident that the events leading to a stroke develop over many years, even decades, before the patient is admitted acutely to a stroke care facility as the stroke risk factors silently build the cardiovascular pathology which will eventually cause the stroke. These cardiovascular risk factors are chronic conditions that persist in the stroke survivor, alter recovery, and increase the risk of recurrence. Moreover, the stroke patient is usually elderly and often has associated disabilities and comorbidities that complicate the successful re-integration into the community, and is one of the most complicated medical paths that a person may have to walk through (Figure 4). Stroke is one of the most typical examples of a medical condition which extends horizontally beyond and across the boundaries of the traditional medical specialties and is best served by integrated, collaborative, inclusive, interdisciplinary teamwork.<sup>176</sup>

The 'Stroke Continuum of Care' has been outlined as the stepwise approach to prevention, treatment, and recovery for stroke. Even though patients may follow different trajectories within the Stroke Continuum, with some patients experiencing a once-in-a-lifetime



**Figure 4** The Stroke Continuum. Patient care across the Stroke Continuum: from primordial prevention (maintenance of health) to primary prevention (control of stroke risk factors), acute stroke, secondary prevention and tertiary prevention (minimization of stroke impact). Depending on the stage of the Stroke Continuum in which the stroke patient is encountered, the stroke physician may have different roles and responsibilities. For example: stroke physicians who serve at the acute stroke care setting would preferentially have strong expertise in selecting and implementing interventional procedures, offering best supportive treatment to minimize acute complications, and guiding and evaluating the diagnostic workup to plan the most effective treatments to reduce recurrence risk—typically this would involve specialty physicians of internal medicine, neurology, cardiology, critical care, intensive care and others. stroke physicians who serve at the rehabilitation setting would preferentially have strong expertise in rehabilitation and in the management of chronic complications like dysphagia, malnutrition and related metabolic derangements—typically this would involve specialty physicians of physical medicine and rehabilitation, neurology, internal medicine and others. Stroke physicians who serve at the outpatient clinic and focus mainly on preventing first or recurrent strokes would preferentially have strong expertise in the management of stroke risk factors—typically this would involve specialty physicians of cardiology, neurology, internal medicine, general practitioners and others. Stroke physicians who are engaged with interventional procedures in the hyperacute and acute setting (or else, stroke interventionists) would preferentially have strong expertise in endovascular procedures like interventional neurology, neuroradiology/radiology, neurosurgery, vascular surgery and cardiology. Across the Stroke Continuum, there is a need for multi-disciplinary collaboration and coordination of care, including the complex treatment of cardiovascular conditions with the overarching goal to improve recovery, prevent recurrence, and enhance survival and quality of life for the patient with stroke.

TIA without any sequelae, whereas others suffer severe disabling strokes, eventually most patients will need the services of physicians from different specialties with stroke-specific expertise, as well as of other healthcare professionals including nurses, physical therapists, occupational therapists, speech therapists, social workers, and psychologists.

In this context, the role of the stroke physician is central to assist the patient journey through this marathon. Not to substitute the related medical specialties, but rather to orchestrate them to combine the needed expertise from a range of specialties in comprehensive multidisciplinary concepts for state-of-the-art stroke care. Such multidisciplinary concepts should cover the entire course of the patients from acute event through emergency care to subacute (Stroke unit) care to long-term diagnostic workup and risk factor monitoring and treatment.

The integrated model of stroke care is implemented in several national health care systems like in the United Kingdom<sup>177,178</sup> and Canada,<sup>179</sup> but there is still heterogeneity globally and further

harmonization is warranted.<sup>180</sup> The recognition and certification of Stroke Medicine as an official subspecialty of the aforementioned specialties like is already the case in the United Kingdom<sup>178</sup> (in which the Stroke Medicine programme is open to all trainees holding certification in one of the following medical specialty: acute internal medicine, cardiology, clinical pharmacology and therapeutics, general internal medicine, geriatric medicine, neurology and rehabilitation medicine), and the implementation of specific subspecialty curricula<sup>177</sup> that are preferentially harmonized across the European Union and beyond will greatly facilitate this process.<sup>181</sup> Additionally, the harmonization of training curricula for stroke interventionists is of paramount importance to increase patient access to timely recanalization, given the still limited availability of skilled medical personnel to cover the needs at population level.<sup>182</sup> We encourage research focusing on the clinical efficacy of multidisciplinary post-acute stroke management clinics to prevent hard clinical outcomes like stroke recurrence, re-hospitalization, and major cardiac events, as well as their cost-efficiency.

## Integrated care for stroke in specific settings: Covid-19 pandemic, low middle income countries, others

### COVID-19

The COVID-19 pandemic had a significant impact on the delivery of stroke care; major reorganizations were required to accommodate the rising numbers of COVID-19 admissions and redeployment of staff.<sup>183,184</sup> Despite the strong association with COVID-19 and IS, numbers of stroke admissions fell during the lockdown, possibly due to milder stroke patients staying home and excess stroke deaths in the community.<sup>185,186</sup> The manifestation of stroke as the first presentation of COVID-19 posed a particular transmission risk in the acute setting, with infection control measures rapidly embedded within the admission pathway to mitigate nosocomial transmission.<sup>183,185</sup> Complex, often young, patients were reported with multifocal large vessel occlusion, hypercoagulability, respiratory insufficiency, and multiple co-morbidities, especially diabetes and heart disease, contributing to increased length of hospital stay, case fatality, and high demand on the MDT.<sup>187–189</sup> Overall, quality of care was preserved, and access to imaging and swallow assessment improved during the lockdown, but definitive hyperacute stroke intervention was significantly affected, particularly thrombolysis delivery.<sup>186,190</sup> Bottlenecks emerged, especially during the surge in transmission, specifically in moving patients along the stroke pathway, underscored by excess hospital admissions due to COVID-19, patients with stroke being managed on 'COVID wards' and an overwhelmed social support services in the community.<sup>187,191</sup> Notably, the acceleration of collaborative clinical and research networks, virtual meetings, and maximizing telemedicine throughout the whole stroke pathway, including pre-hospital, were opportunities that emerged from these challenging times that may have a lasting legacy.<sup>183,184</sup>

### Low-to-middle income countries

Low-to-middle income countries (LMICs) currently harbour 70% of the global stroke burden but are the least equipped in providing stroke management.<sup>192</sup> An ageing population, urbanization leading to an increased prevalence of modifiable risk factors such as hypertension, obesity, diabetes, and hypercholesterolaemia have an additive role.<sup>193</sup> Regional factors such as infection (e.g. HIV) and air pollution also contribute in varying degrees.<sup>194,195</sup> Furthermore, primary and secondary stroke prevention are not fully optimized compared with high-income countries (HICs).<sup>196</sup> Stroke care models in HICs have had a limited transition to LMICs due to the prohibitive costs and cultural variations. As a result, adaptations have arisen, for example, task shifting involving community healthcare workers and carers, hub and spoke models supported by telemedicine, physician and specialist-led stroke services but unsupported by region-specific evidence.<sup>196</sup> The vast majority of LMICs have an unselected approach to stroke management, accounting for very poor outcomes.<sup>197</sup> Simple yet effective interventions may have to be the focus in LMICs, invigorated by innovation and supported by research to demonstrate benefit.

## Competing disease presentations, prioritization of treatment during acute stroke

Common concomitant diseases that may precede or accompany acute stroke and require timely cardiological workup and intervention besides AF are heart failure and ACS, as they often determine the patients' outcomes. Patients with IS have a high 1-year risk of major adverse cardiovascular events with the highest risk within the first 30 days after the ischaemic event.<sup>198,199</sup> The extent of acute infarct size and stroke presentation often correlates with the severity of cardiac involvement. Apart from pre-existing CVD, heart failure can acutely occur as neurogenic stress or Takotsubo cardiomyopathy. In the echocardiographic examination or extended imaging by cardiac MRI they reveal reduced systolic function and/or wall motion abnormalities.<sup>200,201</sup> Electrocardiographic changes and arrhythmias (usually tachyarrhythmias, in particular AF) are common occurring in every fourth stroke patient, with the incidence being highest during the first day after stroke,<sup>202</sup> and elevated cardiac enzymes including creatine kinase major bleeding or troponins and natriuretic peptides are observed frequently. In IS patients with no history of cardiac disease, the occurrence of signs of cardiac damage was more than 50%.<sup>203</sup>

The term stroke-heart syndrome<sup>204,205</sup> comprises the neuro-visceral damage observed in context with cerebral injury. It can be predicted by clinical and routine laboratory variables, which usually identify older and sicker patients.<sup>203</sup> Multiple causes for stroke-induced alterations in the neurocardiogenic axis have been discussed. Besides neurogenic, endocrine (e.g. hypothalamic-pituitary-adrenal axis), and psychological stress, an enhanced inflammatory and immune response, a temporary disruption of the blood-brain barrier and autonomic imbalance have been discussed.<sup>206–208</sup>

The interpretation of cardiac abnormalities in the context with acute stroke remains a challenge since alterations may be transient in nature with complete recovery. But, they may also lead to deterioration and chronic impairment. Whereas patients with high risk of adverse cardiac events need to be identified for targeted intervention, over-diagnosis, and treatment based on cardiac markers alone needs to be avoided.

### Treatment implications

Tachyarrhythmic episodes may require prompt rate control or cardioversion if haemodynamically unstable. Commonly, betablockers, non-dihydropyridine calcium channel blockers respecting their negative inotropic actions, and digoxin with a delayed effect are used. Amiodarone can also be administered for rapid rate control and eventually cardioversion. Anticoagulation should be instituted as soon as deemed safe post stroke.

Whereas heart failure therapy according to guidelines should be instituted upon diagnosis and carefully up-titrated balanced with infarct-related needs, e.g. optimized lower blood pressure boundaries, mechanical circulatory support in heart failure needs to be weighed in context with the overall holistic prognosis, and instituted after careful decision in the stroke-heart team. A frequent differential diagnosis in the context of markers of myocardial damage, e.g., ECG

abnormalities up to ST segment elevations, enzyme elevations, and cardiac dysfunction that need timely attention is ACS. Invasive diagnostics and the potential need of dual antiplatelet therapy for conservative treatment of an ACS or after percutaneous coronary intervention require interdisciplinary decision-making and careful risk benefit assessment. However, a routine measurement of troponins on admission for acute stroke needs to be viewed critically. Using modern troponin assays, elevations are observed in more than 50% of admissions.<sup>209</sup> Despite a higher risk of adverse outcomes, only a minority of patients have a classical ACS. Which patients qualify for invasive diagnostics and more aggressive ACS treatment is subject of the PRediction of Acute Coronary Syndrome in Acute Ischaemic StrokE study (NCT03609385).

## Patient perspective

Stroke is an unexpected, and for most people, a life-changing event, and it is important to remember that every patients' experience will be unique. The trajectory will differ between patients, and their perceptions and experiences will be influenced by the stroke sequelae, the care and treatment they receive, the ongoing support available to them, and their ability to adapt/adjust. For many patients and their family/caregivers, their main concern following a stroke is the risk of a recurrent event. Therefore, the emphasis is often on secondary stroke prevention, and lifestyle changes are necessitated; these must be individually tailored to the patient. However, for those with a severely disabling stroke, prevention of recurrence is generally a lower priority. For many patients finding the cause of their stroke is important to enable them to reduce their chances of recurrence. However, the aetiology of the stroke is often not immediately apparent and may require ongoing, and sometimes protracted, investigation to ascertain the cause; in about 30%, the cause will remain unknown,<sup>210</sup> and this heightens anxiety and can significantly impair recovery.

Stroke has a significant psychological impact as well as physical side-effects. Post-stroke depression and anxiety are common<sup>211–215</sup> and can significantly impact patients' ability, motivation, and engagement with essential lifestyle modifications (e.g. medication adherence, exercise, smoking cessation, dietary changes, etc.); for some, the emotional impact of the stroke may only become apparent several months later. Loss of independence, greater reliance on family and friends, inability to return to work, decreases in previous social/leisure activities, disability or reduced physical functioning, cognitive impairment, communication difficulties (reading, speaking, listening), fatigue, effect on relationships, and the financial impact of stroke can all detrimentally affect the patient, impacting their physical and mental health and reducing their quality of life (and that of their family). It is also imperative to consider the impact of socioeconomic factors,<sup>216,217</sup> such as health literacy, housing conditions, access to affordable and nutritious food, personal safety, transport, social support etc., on an individual's capacity for resilience and ability to implement lifestyle changes necessary to promote recovery and reduce recurrence.

Ongoing support, listening to the patient and providing personalized education, information, and advice in simple terms with consistent messages are important throughout the patient journey and

continuity of care is essential. Integrated care for stroke advocated in this consensus document requires streamlining of care pathways and MDT working to optimize patient care and improve patient outcomes. Central to the success of integrated care is greater patient and family/caregiver involvement in planning and co-producing support packages and input and feedback on optimizing stroke care pathways.

## Long-term post-stroke management

Emerging evidence suggests that comprehensive pragmatic care pathways with continued post-hospital involvement of the multidisciplinary stroke team could reduce the longer-term health burden of stroke.<sup>218</sup> Further high-quality studies are needed to inform sustainable long-term care pathways for long-term improvement in clinical and patient-reported outcomes among stroke patients.

## Consensus statements

The co-occurring and inter-linked nature of CVD requires an integrated care action plan to prevent, identify, treat, and rehabilitate people. This targets the prevention of recurrent stroke, improves patient functional status and symptoms, and manages cardiovascular risk factors, comorbidities, and lifestyle changes

A post-stroke ABC pathway is proposed as a more holistic approach to integrated stroke care and would include three pillars of management:

- A: Appropriate Antithrombotic therapy.
- B: Better functional and psychological status.
- C: Cardiovascular risk factors and Comorbidity optimization (including lifestyle changes).

Appropriate thromboprophylaxis should be targeted to the underlying comorbidity, for example, anticoagulation for patients with AF.

- When stroke patients have both AF and vascular disease, anticoagulation monotherapy would suffice.
- In high-risk stable atherosclerotic vascular disease patients *without* AF, combination therapy with rivaroxaban 2.5 mg bid and aspirin provides some benefits on CVD events (including on stroke) *even in the absence of associated AF*, but at the risk of more major bleeding.
- In the absence of AF, antiplatelet drugs are used for secondary stroke prevention for non-cardioembolic stroke with either aspirin and clopidogrel or ticagrelor. Both the combination of clopidogrel and aspirin and ticagrelor and aspirin have been found to be superior to aspirin alone for 90-day treatment of acute minor strokes and high-risk TIAs. The combination of clopidogrel and aspirin has also been utilized for intracranial atherosclerotic ISs.

Better functional and psychological status requires care packages and management pathways to be established and implemented, including tailored rehabilitation and personalized appropriately to the patient's needs, both in hospital, during rehabilitation, and post-

discharge. Assessment of PSD, anxiety, and cognitive impairment should be undertaken as part of post-stroke care, with appropriate intervention where required.

Cardiovascular risk factors and comorbidities are common in stroke patients, and all need to be considered and addressed in a holistic manner, with treatment targets as per CVD prevention guidelines.

- A considerable burden of previously unknown AF can be detected when long-term monitoring is applied in at-risk patients.

Across the stroke continuum, there is a need for multi-disciplinary collaboration and coordination of care, including the complex treatment of cardiovascular conditions with the overarching goal to improve recovery, prevent recurrence, and enhance survival and quality of life for the patient with stroke.

Competing disease presentations in the context with acute stroke remains a challenge and may also lead to deterioration and chronic impairment. Over-diagnosis and treatment based on cardiac markers alone needs to be avoided.

Central to the success of integrated care for stroke is greater patient and family/caregiver involvement in planning and co-producing support packages, and input and feedback on optimizing stroke care pathways.

## Supplementary material

Supplementary material is available at *European Heart Journal* online.

**Conflict of interest:** G.Y.H.L.: Consultant and speaker for BMS/Pfizer, Boehringer Ingelheim and Daiichi-Sankyo. No fees are received personally. Laura Benjamin is supported by a Wellcome Trust Fellowship (222102/Z/20/Z) and reports research funding from GlaxoSmithKline and honorarium from Merck & Co. G.B.: Speaker's fees of small amount from Medtronic, Boston, Boehringer Ingelheim and Bayer. W.D. reports personal fees and research support from Aimediq, Bayer, Boehringer Ingelheim, Lilly, Medtronic, Vifor Pharma. M.F.: Consultant for AstraZeneca and Lumosa; scientific advisory board, Simcere USA. D.A.L. has received investigator-initiated educational grants from Bristol-Myers Squibb (BMS); speaker for Bayer, Boehringer Ingeheim, and BMS/Pfizer; consultant for BMS and Boehringer Ingelheim. R.L.: Consultant fees from St Jude Medical/Abbott, Biotronik, Medtronic and Boston Scientific, funding from the European Union's Horizon 2020 research and innovation programme under grant agreement no 847999. D.L.: National Clinical Director for Stroke Medicine, NHS England & Wales; previous speaking honoraria from Bayer, Medtronic. R.S. has received lecture fees and advisory board fees from BMS/Pfizer outside this work.

## References

- Fischer U, de Sousa D A, Norrving B, Caso V. Status and perspectives of acute stroke care in Europe. *Stroke* 2018;**49**:2281–2282.
- Lip GYH. The ABC pathway: an integrated approach to improve AF management. *Nat Rev Cardiol* 2017;**14**:627–628.
- Field M, Kuduvalli M, Torella F, McKay V, Khalatbari A, Lip GY. Integrated care pathways and the aortovascular hub. *Thromb Haemost* 2022;**122**(2):177–180.
- Moudallel S, van den Bemt BJF, Zwikker H, de Veer A, Rydant S, Dijk LV, et al. Association of conflicting information from healthcare providers and poor shared decision making with suboptimal adherence in direct oral anticoagulant treatment: a cross-sectional study in patients with atrial fibrillation. *Patient Educ Couns* 2021;**104**:155–162.
- Hindricks G, Potpara T, Dagres N, Arbelo E, Bax JJ, Blomstrom-Lundqvist C, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation developed in collaboration with the European Association of Cardio-Thoracic Surgery (EACTS): the Task Force for the diagnosis and management of atrial fibrillation of the European Society of Cardiology (ESC) Developed with the special contribution of the European Heart Rhythm Association (EHRA) of the ESC. *Eur. Heart J* 2021;**42**(5):373–498.
- Chao TF, Joung B, Takahashi Y, Lim TW, Choi EK, Chan YH, et al. 2021 Focused update consensus guidelines of the Asia Pacific Heart Rhythm Society on stroke prevention in atrial fibrillation: executive summary. *Thromb Haemost* 2022;**122**(1):20–47.
- Romiti GF, Pastori D, Rivera-Caravaca JM, Ding WY, Gue YX, Menichelli D, et al. Adherence to the 'atrial fibrillation better care' (ABC) pathway in patients with atrial fibrillation: impact on clinical outcomes—a systematic review and meta-analysis of 285,000 patients. *Thromb Haemost* 2022;**122**(3):406–414.
- Proietti M, Romiti GF, Olshansky B, Lane DA, Lip GYH. Comprehensive management with the ABC (atrial fibrillation better care) pathway in clinically complex patients with atrial fibrillation: a post hoc ancillary analysis from the affirm trial. *J Am Heart Assoc* 2020;**9**:e014932.
- Guo Y, Lane DA, Wang L, Zhang H, Wang H, Zhang W, et al. Mobile health technology to improve care for patients with atrial fibrillation. *J Am Coll Cardiol* 2020;**75**:1523–1534.
- Guo Y, Lane DA, Chen Y, Lip GYH, m AFAITi. Regular bleeding risk assessment associated with reduction in bleeding outcomes: the mafa-ii randomized trial. *Am J Med* 2020;**133**:1195–1202.e2.
- Guo Y, Guo J, Shi X, Yao Y, Sun Y, Xia Y, et al. Mobile health technology-supported atrial fibrillation screening and integrated care: a report from the mafa-ii trial long-term extension cohort. *Eur J Intern Med* 2020;**82**:105–111.
- Michel P, Odier C, Rutgers M, Reichhart M, Maeder P, Meuli R, et al. The Acute Stroke Registry and Analysis of Lausanne (ASTRAL): design and baseline analysis of an ischemic stroke registry including acute multimodal imaging. *Stroke* 2010;**41**:2491–2498.
- Ahmadi M, Laumeier I, Ihl T, Steinicke M, Ferse C, Endres M, et al. A support programme for secondary prevention in patients with transient ischaemic attack and minor stroke (INSPIRE-TMS): an open-label, randomised controlled trial. *Lancet Neurol* 2020;**19**:49–60.
- Toell T, Boehme C, Mayer L, Krebs S, Lang C, Willeit K, et al. Pragmatic trial of multifaceted intervention (STROKE-CARD care) to reduce cardiovascular risk and improve quality-of-life after ischaemic stroke and transient ischaemic attack—study protocol. *BMC Neurol* 2018;**18**:187.
- Hempler I, Woitha K, Thielhorn U, Farin E. Post-stroke care after medical rehabilitation in Germany: a systematic literature review of the current provision of stroke patients. *BMC Health Serv Res* 2018;**18**:468.
- Norrving B, Barrick J, Davalos A, Dichgans M, Cordonnier C, Guekht A, et al. Action plan for stroke in Europe 2018–2030. *Eur Stroke J* 2018;**3**:309–336.
- Chiu CC, Lin HF, Lin CH, Chang HT, Hsien HH, Hung KW, et al. Multidisciplinary care after acute care for stroke: a prospective comparison between a multidisciplinary post-acute care group and a standard group matched by propensity score. *Int J Environ Res Public Health* 2021;**18**:7696.
- Kamel H, Okin PM, Elkind MS, Iadecola C. Atrial fibrillation and mechanisms of stroke: time for a new model. *Stroke* 2016;**47**:895–900.
- Lip GYH, Ntaios G. Novel clinical concepts in thrombosis: integrated care for stroke management—easy as ABC. *Thromb Haemost* 2022;**122**(3):316–319.
- Hilkens NA, Algra A, Diener HC, Bath PM, Csiba L, Hacke W, et al. Balancing benefits and risks of long-term antiplatelet therapy in noncardioembolic transient ischemic attack or stroke. *Stroke* 2021;**52**(10):3258–3265.
- Ntaios G, Lip GY. Difficult situations in anticoagulation after stroke: between Scylla and Charybdis. *Curr Opin Neurol* 2016;**29**:42–48.
- Gargiulo G, Goette A, Tijssen J, Eckardt L, Lewalter T, Vranckx P, et al. Safety and efficacy outcomes of double vs. Triple antithrombotic therapy in patients with atrial fibrillation following percutaneous coronary intervention: a systematic review and meta-analysis of non-vitamin K antagonist oral anticoagulant-based randomized clinical trials. *Eur Heart J* 2019;**40**:3757–3767.
- Noubiap JJ, Agbaedeng TA, Tochie JN, Nkeck JR, Ndoadoumgue AL, Fitzgerald JL, et al. Meta-analysis comparing the frequency of carotid artery stenosis in patients with atrial fibrillation and vice versa. *Am J Cardiol* 2021;**138**:72–79.
- Guedeney P, Collet JP. Antithrombotic therapy in acute coronary syndromes: current evidence and ongoing issues regarding early and late management. *Thromb Haemost* 2021;**121**:854–866.
- Lee SR, Rhee TM, Kang DY, Choi EK, Oh S, Lip GYH. Meta-analysis of oral anti-coagulant monotherapy as an antithrombotic strategy in patients with stable coronary artery disease and nonvalvular atrial fibrillation. *Am J Cardiol* 2019;**124**:879–885.

26. Yasuda S, Kaikita K, Akao M, Aki J, Matoba T, Nakamura M, et al. Antithrombotic therapy for atrial fibrillation with stable coronary disease. *N Engl J Med* 2019;**381**: 1103–1113.
27. Lip GYH, Collet JP, Haude M, Byrne R, Chung EH, Fauchier L, et al. 2018 Joint European consensus document on the management of antithrombotic therapy in atrial fibrillation patients presenting with acute coronary syndrome and/or undergoing percutaneous cardiovascular interventions: a joint consensus document of the European Heart Rhythm Association (EHRA), European Society of Cardiology working group on thrombosis, European Association of Percutaneous Cardiovascular Interventions (EAPCI), and European Association of Acute Cardiac Care (ACCA) endorsed by the Heart Rhythm Society (HRS), Asia-Pacific Heart Rhythm Society (APHRS), Latin America Heart Rhythm Society (LAHRS), and Cardiac Arrhythmia Society of Southern Africa (CASSA). *Europace* 2019;**19**:192–193.
28. Naylor AR, Ricco JB, de Borst GJ, Debus S, de Haro J, Halliday A, et al. Editor's choice—management of atherosclerotic carotid and vertebral artery disease: 2017 clinical practice guidelines of the European Society for Vascular Surgery (ESVS). *Eur J Vasc Endovasc Surg* 2018;**55**:3–81.
29. Bonati LH, Kakkos S, Berkefeld J, de Borst GJ, Bulbulia R, Halliday A, et al. European stroke organisation guideline on endarterectomy and stenting for carotid artery stenosis. *Eur Stroke J* 2021;**6**:1–XLVII.
30. Huang YC, Huang YC, Cheng YC, Chen M. Choice of antithrombotic therapy for patients with atrial fibrillation undergoing carotid angioplasty and stenting: a nationwide population-based study. *Sci Rep* 2022;**12**:1417.
31. Eikelboom JW, Connolly SJ, Bosch J, Dagenais GR, Hart RG, Shestakova O, et al. Rivaroxaban with or without aspirin in stable cardiovascular disease. *N Engl J Med* 2017;**377**:1319–1330.
32. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2014;**45**:2160–2236.
33. Sacco RL, Diener HC, Yusuf S, Cotton D, Ounpuu S, Lawton WA, et al. Aspirin and extended-release dipyridamole versus clopidogrel for recurrent stroke. *N Engl J Med* 2008;**359**:1238–1251.
34. Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al. Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. *N Engl J Med* 2013;**369**:11–19.
35. Wang Y, Zhao X, Lin J, Li H, Johnston SC, Lin Y, et al. Association between cyp2c19 loss-of-function allele status and efficacy of clopidogrel for risk reduction among patients with minor stroke or transient ischemic attack. *Jama* 2016;**316**:70–78.
36. Johnston SC, Easton JD, Farrant M, Barsan W, Conwit RA, Elm JJ, et al. Clopidogrel and aspirin in acute ischemic stroke and high-risk tia. *N Engl J Med* 2018;**379**: 215–225.
37. Meschia JF, Walton RL, Farrugia LP, Ross OA, Elm JJ, Farrant M, et al. Efficacy of clopidogrel for prevention of stroke based on cyp2c19 allele status in the point trial. *Stroke* 2020;**51**:2058–2065.
38. Kleindorfer DO, Towfighi A, Chaturvedi S, Cockroft KM, Gutierrez J, Lombardi-Hill D, et al. 2021 guideline for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline from the American Heart Association/American Stroke Association. *Stroke* 2021;**52**:e364–e467.
39. Johnston SC, Amarenco P, Denison H, Evans SR, Himmelmann A, James S, et al. Ticagrelor and aspirin or aspirin alone in acute ischemic stroke or TIA. *N Engl J Med* 2020;**383**:207–217.
40. Amarenco P, Denison H, Evans SR, Himmelmann A, James S, Knutsson M, et al. Ticagrelor added to aspirin in acute nonsevere ischemic stroke or transient ischemic attack of atherosclerotic origin. *Stroke* 2020;**51**:3504–3513.
41. Wang Y, Meng X, Wang A, Xie X, Pan Y, Johnston SC, et al. Ticagrelor versus clopidogrel in CYP2C19 loss-of-function carriers with stroke or TIA. *N Engl J Med* 2021;**385**:2520–2530.
42. Toyoda K, Uchiyama S, Yamaguchi T, Easton JD, Kimura K, Hoshino H, et al. Dual antiplatelet therapy using cilostazol for secondary prevention in patients with high-risk ischaemic stroke in japan: a multicentre, open-label, randomised controlled trial. *Lancet Neurol* 2019;**18**:539–548.
43. Stroke Unit Trialists' Collaboration. Organised inpatient (stroke unit) care for stroke. *Cochrane Database Syst Rev*. 2013; **2013**:Cd000197
44. Langhorne P, Fearon P, Ronning OM, Kaste M, Palomaki H, Vemmos K, et al. Stroke unit care benefits patients with intracerebral hemorrhage: systematic review and meta-analysis. *Stroke* 2013;**44**:3044–3049.
45. Seners P, Turc G, Oppenheim C, Baron JC. Incidence, causes and predictors of neurological deterioration occurring within 24 h following acute ischaemic stroke: a systematic review with pathophysiological implications. *J Neurol Neurosurg Psychiatry* 2015;**86**:87–94.
46. Amin-Hanjani S, See AP, Du X, Rose-Finnell L, Pandey DK, Chen YF, et al. Natural history of hemodynamics in vertebrobasilar disease: temporal changes in the veritas study cohort. *Stroke* 2020;**51**:3295–3301.
47. Amin-Hanjani S, Stapleton CJ, Du X, Rose-Finnell L, Pandey DK, Elkind MSV, et al. Hypoperfusion symptoms poorly predict hemodynamic compromise and stroke risk in vertebrobasilar disease. *Stroke* 2019;**50**:495–497.
48. Thieme H, Morkisch N, Mehrholz J, Pohl M, Behrens J, Borgetto B, et al. Mirror therapy for improving motor function after stroke. *Cochrane Database Syst Rev* 2018;**7**:CD008449.
49. Mehrholz J, Pohl M, Platz T, Kugler J, Elsner B. Electromechanical and robot-assisted arm training for improving activities of daily living, arm function, and arm muscle strength after stroke. *Cochrane Database Syst Rev* 2018;**9**:CD006876.
50. Mehrholz J, Thomas S, Elsner B. Treadmill training and body weight support for walking after stroke. *Cochrane Database Syst Rev* 2017;**8**:CD002840.
51. Mehrholz J, Thomas S, Werner C, Kugler J, Pohl M, Elsner B. Electromechanical-assisted training for walking after stroke. *Cochrane Database Syst Rev* 2017;**5**:CD006185.
52. Stinear CM, Lang CE, Zeiler S, Byblow WD. Advances and challenges in stroke rehabilitation. *Lancet Neurol* 2020;**19**:348–360.
53. Regan EW, Handlery R, Stewart JC, Pearson JL, Wilcox S, Fritz S. Integrating survivors of stroke into exercise-based cardiac rehabilitation improves endurance and functional strength. *J Am Heart Assoc* 2021;**10**:e017907.
54. Middleton S, McElduff P, Ward J, Grimshaw JM, Dale S, D'Este C, et al. Implementation of evidence-based treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC): a cluster randomised controlled trial. *Lancet* 2011;**378**:1699–1706.
55. Ntaios G, Gioulekas F, Papavasileiou V, Strbian D, Michel P. Astral, dragon and sedan scores predict stroke outcome more accurately than physicians. *Eur J Neurol* 2016;**23**:1651–1657.
56. Ntaios G, Faouzi M, Ferrari J, Lang W, Vemmos K, Michel P. An integer-based score to predict functional outcome in acute ischemic stroke: the astral score. *Neurology* 2012;**78**:1916–1922.
57. Papavasileiou V, Milionis H, Michel P, Makaritsis K, Vemmos A, Koroboki E, et al. Astral score predicts 5-year dependence and mortality in acute ischemic stroke. *Stroke* 2013;**44**:1616–1620.
58. Liu G, Ntaios G, Zheng H, Wang Y, Michel P, Wang DZ, et al. External validation of the astral score to predict 3- and 12-month functional outcome in the china national stroke registry. *Stroke* 2013;**44**:1443–1445.
59. Saver JL, Chaisinanunkul N, Campbell BCV, Grotta JC, Hill MD, Khatri P, et al. Standardized nomenclature for modified rankin scale global disability outcomes: consensus recommendations from stroke therapy academic industry roundtable xi. *Stroke* 2021;**52**(9):3054–3062.
60. Mosalski S, Shiner CT, Lannin NA, Cadilhac DA, Faux SG, Kim J, et al. Increased relative functional gain and improved stroke outcomes: a linked registry study of the impact of rehabilitation. *J Stroke Cerebrovasc Dis* 2021;**30**:106015.
61. Zeng YY, Wu MX, Geng DD, Cheng L, Zhou SN, Fan KL, et al. Early-onset depression in stroke patients: effects on unfavorable outcome 5 years post-stroke. *Front Psychiatry* 2021;**12**:56981.
62. Towfighi A, Ovbiagele B, Hussein NE, Hackett ML, Jorge RE, Kissela BM, et al. Poststroke depression: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2017;**48**: e30–e43.
63. Verdelho A, Wardlaw J, Pavlovic A, Pantoni L, Godefroy O, Duering M, et al. Cognitive impairment in patients with cerebrovascular disease: a white paper from the links between stroke ESO dementia committee. *Eur Stroke J* 2021;**6**:5–17.
64. Leys D, Hénon H, Mackowiak-Cordoliani M-A, Pasquier F. Poststroke dementia. *Lancet Neurol* 2005;**4**:752–759.
65. Broussy S, Rouanet F, Lesaine E, Domecq S, Kret M, Maugeais M, et al. Post-stroke pathway analysis and link with one year sequelae in a french cohort of stroke patients: the papasepa protocol study. *BMC Health Serv Res* 2019;**19**:770.
66. Aziz AF A, Nordin NA M, Ali MF, Abd Aziz NA, Sulong S, Aljunid SM. The integrated care pathway for post stroke patients (ICAPPS): a shared care approach between stakeholders in areas with limited access to specialist stroke care services. *BMC Health Serv Res* 2017;**17**:35.
67. Platz T. Evidence-based guidelines and clinical pathways in stroke rehabilitation-an international perspective. *Front Neurol* 2019;**10**:200.
68. Feigin VL, Roth GA, Naghavi M, Parmar P, Krishnamurthi R, Chugh S, et al. Global burden of stroke and risk factors in 188 countries, during 1990–2013: a systematic analysis for the global burden of disease study 2013. *Lancet Neurol* 2016;**15**: 913–924.
69. O'Donnell MJ, Xavier D, Liu L, Zhang H, Chin SL, Rao-Melacini P, et al. Risk factors for ischaemic and intracerebral haemorrhagic stroke in 22 countries (the INTERSTROKE study): a case-control study. *Lancet* 2010;**376**:112–123.
70. Heuschmann PU, Kircher J, Nowe T, Dittrich R, Reiner Z, Cifkova R, et al. Control of main risk factors after ischaemic stroke across Europe: data from the stroke-specific module of the Euroaspire iii survey. *Eur J Prev Cardiol* 2015;**22**:1354–1362.



71. Rees K, Takeda A, Martin N, Ellis L, Wijesekara D, Vepa A, et al. Mediterranean-style diet for the primary and secondary prevention of cardiovascular disease. *Cochrane Database Syst Rev* 2019;**3**:Cd009825.
72. Sacks FM, Svetkey LP, Vollmer WM, Appel LJ, Bray GA, Harsha D, et al. Effects on blood pressure of reduced dietary sodium and the dietary approaches to stop hypertension (DASH) diet. Dash-sodium collaborative research group. *N Engl J Med* 2001;**344**:3–10.
73. de Lorgeril M, Salen P, Martin JL, Monjaud I, Delaye J, Mamelle N. Mediterranean diet, traditional risk factors, and the rate of cardiovascular complications after myocardial infarction: final report of the Lyon diet heart study. *Circulation* 1999;**99**: 779–785.
74. Estruch R, Ros E, Salas-Salvadó J, Covas MI, Corella D, Arós F, et al. Primary prevention of cardiovascular disease with a mediterranean diet supplemented with extra-virgin olive oil or nuts. *N Engl J Med* 2018;**378**:e34.
75. Kastorini CM, Milionis HJ, Kantas D, Bika E, Nikolaou V, Vemmos KN, et al. Adherence to the mediterranean diet in relation to ischemic stroke nonfatal events in nonhypercholesterolemic and hypercholesterolemic participants: results of a case/case-control study. *Angiology* 2012;**63**:509–515.
76. Tong TYN, Appleby PN, Key TJ, Dahm CC, Overvad K, Olsen A, et al. The associations of major foods and fibre with risks of ischaemic and haemorrhagic stroke: a prospective study of 418 329 participants in the epic cohort across nine European countries. *Eur Heart Journal* 2020;**41**:2632–2640.
77. Aune D, Giovannucci E, Boffetta P, Fadnes LT, Keum N, Norat T, et al. Fruit and vege intake and the risk of cardiovascular disease, total cancer and all-cause mortality—a systematic review and dose-response meta-analysis of prospective studies. *Int J Epidemiol* 2017;**46**:1029–1056.
78. Fung TT, Stampfer MJ, Manson JE, Rexrode KM, Willett WC, Hu FB. Prospective study of major dietary patterns and stroke risk in women. *Stroke* 2004;**35**: 2014–2019.
79. He FJ, Nowson CA, MacGregor GA. Fruit and vegetable consumption and stroke: meta-analysis of cohort studies. *Lancet* 2006;**367**:320–326.
80. Turan TN, Nizam A, Lynn MJ, Egan BM, Le NA, Lopes-Virella MF, et al. Relationship between risk factor control and vascular events in the sammpris trial. *Neurology* 2017;**88**:379–385.
81. Judd SE, Gutiérrez OM, Newby PK, Howard G, Howard VJ, Locher JL, et al. Dietary patterns are associated with incident stroke and contribute to excess risk of stroke in black americans. *Stroke* 2013;**44**:3305–3311.
82. Zhao W, Tang H, Yang X, Luo X, Wang X, Shao C, et al. Fish consumption and stroke risk: a meta-analysis of prospective cohort studies. *J Stroke Cerebrovasc Dis* 2019;**28**:604–611.
83. Filippou CD, Tsioufis CP, Thomopoulos CG, Mihos CC, Dimitriadis KS, Sotiropoulou LI, et al. Dietary approaches to stop hypertension (DASH) diet and blood pressure reduction in adults with and without hypertension: a systematic review and meta-analysis of randomized controlled trials. *Adv Nutr* 2020;**11**: 1150–1160.
84. Nagata C, Takatsuka N, Shimizu N, Shimizu H. Sodium intake and risk of death from stroke in Japanese men and women. *Stroke* 2004;**35**:1543–1547.
85. Strazzullo P, D'Elia L, Kandala NB, Cappuccio FP. Salt intake, stroke, and cardiovascular disease: meta-analysis of prospective studies. *BMJ* 2009;**339**:b4567.
86. Wing RR, Lang W, Wadden TA, Safford M, Knowler WC, Bertoni AG, et al. Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes. *Diabetes care* 2011;**34**: 1481–1486.
87. Petersen KF, Dufour S, Befroy D, Lehrke M, Hendler RE, Shulman GI. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. *Diabetes* 2005;**54**: 603–608.
88. Schauer PR, Kashyap SR, Wolski K, Brethauer SA, Kirwan JP, Pothier CE, et al. Bariatric surgery versus intensive medical therapy in obese patients with diabetes. *N Engl J Med* 2012;**366**:1567–1576.
89. Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DIRECT): an open-label, cluster-randomised trial. *Lancet* 2018;**391**:541–551.
90. LeBlanc ES, Patnode CD, Webber EM, Redmond N, Rushkin M, O'Connor EA. Behavioral and pharmacotherapy weight loss interventions to prevent obesity-related morbidity and mortality in adults: updated evidence report and systematic review for the us preventive services task force. *Jama* 2018;**320**: 1172–1191.
91. Sjöström L, Peltonen M, Jacobson P, Sjöström CD, Karason K, Wedel H, et al. Bariatric surgery and long-term cardiovascular events. *Jama* 2012;**307**:56–65.
92. Lee CD, Folsom AR, Blair SN. Physical activity and stroke risk: a meta-analysis. *Stroke* 2003;**34**:2475–2481.
93. Warburton DER, Bredin SSD. Health benefits of physical activity: a systematic review of current systematic reviews. *Curr Opin Cardiol* 2017;**32**:541–556.
94. Paixão C, Dias CM, Jorge R, Carraça EV, Yannakoulia M, de Zwaan M, et al. Successful weight loss maintenance: a systematic review of weight control registries. *Obes Rev* 2020;**21**:e13003.
95. D'Isabella NT, Shkredova DA, Richardson JA, Tang A. Effects of exercise on cardiovascular risk factors following stroke or transient ischemic attack: a systematic review and meta-analysis. *Clin Rehabil* 2017;**31**:1561–1572.
96. English C, Janssen H, Crowfoot G, Bourne J, Callister R, Dunn A, et al. Frequent, short bouts of light-intensity exercises while standing decreases systolic blood pressure: breaking up sitting time after stroke (BUST-stroke) trial. *Int J Stroke* 2018;**13**:932–940.
97. Billinger SA, Arena R, Bernhardt J, Eng JJ, Franklin BA, Johnson CM, et al. Physical activity and exercise recommendations for stroke survivors: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2014;**45**:2532–2553.
98. Deijl IA, Van Schaik SM, Van Wegen EE, Weinstein HC, Kwakkel G, Van den Berg-Vos RM. Lifestyle interventions to prevent cardiovascular events after stroke and transient ischemic attack: systematic review and meta-analysis. *Stroke* 2017;**48**: 174–179.
99. Lennon O, Galvin R, Smith K, Doody C, Blake C. Lifestyle interventions for secondary disease prevention in stroke and transient ischaemic attack: a systematic review. *Eur J Prev Cardiol* 2014;**21**:1026–1039.
100. Meschia JF, Bushnell C, Boden-Albala B, Braun LT, Bravata DM, Chaturvedi S, et al. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2014;**45**:3754–3832.
101. Ois A, Gomis M, Rodriguez-Campello A, Cuadrado-Godia E, Jimenez-Conde J, Pont-Sunyer C, et al. Factors associated with a high risk of recurrence in patients with transient ischemic attack or minor stroke. *Stroke* 2008;**39**:1717–1721.
102. Ricci C, Wood A, Muller D, Gunter MJ, Agudo A, Boeing H, et al. Alcohol intake in relation to non-fatal and fatal coronary heart disease and stroke: epic-cvd case-cohort study. *BMJ* 2018;**361**:k934.
103. Evans-Hudnall GL, Stanley MA, Clark AN, Bush AL, Resnicow K, Liu Y, et al. Improving secondary stroke self-care among underserved ethnic minority individuals: a randomized clinical trial of a pilot intervention. *J Behav Med* 2014;**37**: 196–204.
104. Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking cessation. *Cochrane Database Syst Rev* 2016; **3**:Cd008286.
105. van den Berg MJ, van der Graaf Y, Deckers JW, de Kanter W, Algra A, Kappelle LJ, et al. Smoking cessation and risk of recurrent cardiovascular events and mortality after a first manifestation of arterial disease. *Am Heart J* 2019;**213**:112–122.
106. Chen J, Li S, Zheng K, Wang H, Xie Y, Xu P, et al. Impact of smoking status on stroke recurrence. *J Am Heart Assoc* 2019;**8**:e011696.
107. Lee PN, Thornton AJ, Forey BA, Hamling JS. Environmental tobacco smoke exposure and risk of stroke in never smokers: an updated review with meta-analysis. *J Stroke Cerebrovasc Dis* 2017;**26**:204–216.
108. Kishore A, Vail A, Majid A, Dawson J, Lees KR, Tyrrell PJ, et al. Detection of atrial fibrillation after ischemic stroke or transient ischemic attack: a systematic review and meta-analysis. *Stroke* 2014;**45**:520–526.
109. Sposato LA, Cipriano LE, Saposnik G, Ruiz Vargas E, Riccio PM, Hachinski V. Diagnosis of atrial fibrillation after stroke and transient ischaemic attack: a systematic review and meta-analysis. *Lancet Neurol* 2015;**14**:377–387.
110. Diederichsen SZ, Haugan KJ, Kronborg C, Graff C, Hojberg S, Kober L, et al. Comprehensive evaluation of rhythm monitoring strategies in screening for atrial fibrillation: insights from patients at risk monitored long term with an implantable loop recorder. *Circulation* 2020;**141**:1510–1522.
111. Boulanger JM, Lindsay MP, Gubitz G, Smith EE, Stotts G, Foley N, et al. Canadian stroke best practice recommendations for acute stroke management: prehospital, emergency department, and acute inpatient stroke care, 6th edition, update 2018. *Int J Stroke* 2018;**13**:949–984.
112. Thijs VN, Brachmann J, Morillo CA, Passman RS, Sanna T, Bernstein RA, et al. Predictors for atrial fibrillation detection after cryptogenic stroke: results from crystal af. *Neurology* 2016;**86**:261–269.
113. Cameron A, Cheng HK, Lee RP, Doherty D, Hall M, Khashayar P, et al. Biomarkers for atrial fibrillation detection after stroke: systematic review and meta-analysis. *Neurology* 2021;**97**:e1775–e1789.
114. Binici Z, Intzlikis T, Nielsen OW, Kober L, Sajadieh A. Excessive supraventricular ectopic activity and increased risk of atrial fibrillation and stroke. *Circulation* 2010; **121**:1904–1911.
115. Poli S, Diederler J, Hartig F, Gotz N, Bauer A, Sachse T, et al. Insertable cardiac monitors after cryptogenic stroke—a risk factor based approach to enhance the detection rate for paroxysmal atrial fibrillation. *Eur J Neurol* 2016;**23**:375–381.
116. Llobart V, Antolin-Fontes A, Bustamante A, Giralto D, Rost NS, Furie K, et al. B-type natriuretic peptides help in cardioembolic stroke diagnosis: pooled data meta-analysis. *Stroke* 2015;**46**:1187–1195.

117. Li YG, Pastori D, Farcomeni A, Yang PS, Jang E, Joung B, et al. A simple clinical risk score (C2HEST) for predicting incident atrial fibrillation in asian subjects: derivation in 471,446 Chinese subjects, with internal validation and external application in 451,199 Korean subjects. *Chest* 2019;**155**:510–518.
118. Gladstone DJ, Dorian P, Spring M, Panzov V, Mamdani M, Healey JS, et al. Atrial premature beats predict atrial fibrillation in cryptogenic stroke: results from the embrace trial. *Stroke* 2015;**46**:936–941.
119. Pala E, Pagola J, Juega J, Francisco-Pascual J, Bustamante A, Penalba A, et al. B-type natriuretic peptide over n-terminal pro-brain natriuretic peptide to predict incident atrial fibrillation after cryptogenic stroke. *Eur J Neurol* 2021;**28**:540–547.
120. Wasser K, Weber-Kruger M, Groschel S, Uphaus T, Liman J, Hamann GF, et al. Brain natriuretic peptide and discovery of atrial fibrillation after stroke: a subanalysis of the find-afrandomised trial. *Stroke* 2020;**51**:395–401.
121. Buchwald F, Norrving B, Petersson J. Atrial fibrillation in transient ischemic attack versus ischemic stroke: a Swedish stroke register (Riksstroke) study. *Stroke* 2016;**47**:2456–2461.
122. Amarenco P, Lavalley PC, Monteiro Tavares L, Labreuche J, Albers GW, Abboud H, et al. Five-year risk of stroke after TIA or minor ischemic stroke. *N Engl J Med* 2018;**378**:2182–2190.
123. Perez MV, Mahaffey KW, Hedlin H, Rumsfeld JS, Garcia A, Ferris T, et al. Large-scale assessment of a smartwatch to identify atrial fibrillation. *N Engl J Med* 2019;**381**:1909–1917.
124. Guo Y, Wang H, Zhang H, Liu T, Liang Z, Xia Y, et al. Mobile photoplethysmographic technology to detect atrial fibrillation. *J Am Coll Cardiol* 2019;**74**:2365–2375.
125. Barrett PM, Komatireddy R, Haaser S, Topol S, Sheard J, Encinas J, et al. Comparison of 24-hour holter monitoring with 14-day novel adhesive patch electrocardiographic monitoring. *Am J Med* 2014;**127**:95.e11–95.e17.
126. Koh KT, Law WC, Zaw WM, Foo DHP, Tan CT, Steven A, et al. Smartphone electrocardiogram for detecting atrial fibrillation after a cerebral ischaemic event: a multicentre randomized controlled trial. *Europace* 2021;**23**(7):1016–1023.
127. Robinson TG, Minhas JS, Miller J. Review of major trials of acute blood pressure management in stroke. *J Cereb Blood Flow Metab* 2022;**42**(3):404–410.
128. Powers WJ, Rabinstein AA, Ackerson T, Adeoye OM, Bambakidis NC, Becker K, et al. Guidelines for the early management of patients with acute ischemic stroke: 2019 update to the 2018 guidelines for the early management of acute ischemic stroke: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke* 2019;**50**:e344–e418.
129. Anderson CS, Huang Y, Lindley RI, Chen X, Arima H, Chen G, et al. Intensive blood pressure reduction with intravenous thrombolysis therapy for acute ischaemic stroke (ENCHANTED): an international, randomised, open-label, blinded-endpoint, phase 3 trial. *Lancet* 2019;**393**:877–888.
130. Mazighi M, Richard S, Lapergue B, Sibon I, Gory B, Berge J, et al. Safety and efficacy of intensive blood pressure lowering after successful endovascular therapy in acute ischaemic stroke (BP-TARGET): a multicentre, open-label, randomised controlled trial. *Lancet Neurol* 2021;**20**:265–274.
131. Anderson CS, Heeley E, Huang Y, Wang J, Stapf C, Delcourt C, et al. Rapid blood-pressure lowering in patients with acute intracerebral hemorrhage. *N Engl J Med* 2013;**368**:2355–2365.
132. Krishnan K, Scutt P, Woodhouse L, Adami A, Becker JL, Berge E, et al. Glyceryl trinitrate for acute intracerebral hemorrhage: results from the efficacy of nitric oxide in stroke (ENOS) trial, a subgroup analysis. *Stroke* 2016;**47**:44–52.
133. Qureshi AI, Palesch YY, Barsan WG, Hanley DF, Hsu CY, Martin RL, et al. Intensive blood-pressure lowering in patients with acute cerebral hemorrhage. *N Engl J Med* 2016;**375**:1033–1043.
134. Sandset EC, Anderson CS, Bath PM, Christensen H, Fischer U, Gasecki D, et al. European Stroke Organisation (ESO) guidelines on blood pressure management in acute ischaemic stroke and intracerebral haemorrhage. *Eur Stroke J* 2021;**6**:11.
135. Capes SE, Hunt D, Malmberg K, Pathak P, Gerstein HC. Stress hyperglycemia and prognosis of stroke in nondiabetic and diabetic patients: a systematic overview. *Stroke* 2001;**32**:2426–2432.
136. Martini SR, Kent TA. Hyperglycemia in acute ischemic stroke: a vascular perspective. *J Cereb Blood Flow Metab* 2007;**27**:435–451.
137. Paciaroni M, Agnelli G, Caso V, Corea F, Ageno W, Alberti A, et al. Acute hyperglycemia and early hemorrhagic transformation in ischemic stroke. *Cerebrovasc Dis* 2009;**28**:119–123.
138. Cerecedo-Lopez CD, Cantu-Aldana A, Patel NJ, Aziz-Sultan MA, Frerichs KU, Du R. Insulin in the management of acute ischemic stroke: a systematic review and meta-analysis. *World Neurosurg* 2020;**136**:e514–e534.
139. Johnston KC, Bruno A, Pauls Q, Hall CE, Barrett KM, Barsan W, et al. Intensive vs standard treatment of hyperglycemia and functional outcome in patients with acute ischemic stroke: the shine randomized clinical trial. *JAMA* 2019;**322**:326–335.
140. Zheng D, Zhao X. Intensive versus standard glucose control in patients with ischemic stroke: a meta-analysis of randomized controlled trials. *World Neurosurg* 2020;**136**:e487–e495.
141. Fuentes B, Ntaios G, Putaala J, Thomas B, Turc G, Diez-Tejedor E, et al. European Stroke Organisation (ESO) guidelines on glycaemia management in acute stroke. *Eur Stroke J* 2018;**3**:5–21.
142. Cosentino F, Grant PJ, Aboyans V, Bailey CJ, Ceriello A, Delgado V, et al. ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the easd. *Eur Heart J* 2019;**2020**:255–323.
143. Diabetes A A. 6. Glycemic targets: standards of medical care in diabetes-2021. *Diabetes care* 2021;**44**:S73–S84.
144. Amarenco P, Labreuche J. Lipid management in the prevention of stroke: review and updated meta-analysis of statins for stroke prevention. *Lancet Neurol* 2009;**8**:453–463.
145. Merwick A, Albers GW, Arsava EM, Ay H, Calvet D, Coutts SB, et al. Reduction in early stroke risk in carotid stenosis with transient ischemic attack associated with statin treatment. *Stroke* 2013;**44**:2814–2820.
146. Flint AC, Conell C, Ren X, Kamel H, Chan SL, Rao VA, et al. Statin adherence is associated with reduced recurrent stroke risk in patients with or without atrial fibrillation. *Stroke* 2017;**48**:1788–1794.
147. Amarenco P, Bogousslavsky J, Callahan A III, Goldstein LB, Hennerici M, Rudolph AE, et al. High-dose atorvastatin after stroke or transient ischemic attack. *N Engl J Med* 2006;**355**:549–559.
148. Judge C, Ruttledge S, Costello M, Murphy R, Loughlin E, Alvarez-Iglesias A, et al. Lipid lowering therapy, low-density lipoprotein level and risk of intracerebral hemorrhage—a meta-analysis. *J Stroke Cerebrovasc Dis* 2019;**28**:1703–1709.
149. McKinney JS, Kostis WJ. Statin therapy and the risk of intracerebral hemorrhage: a meta-analysis of 31 randomized controlled trials. *Stroke* 2012;**43**:2149–2156.
150. Mach F, Baigent C, Catapano AL, Koskinas KC, Casula M, Badimon L, et al. ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk. *Eur Heart J* 2019;**2020**:111–188.
151. Amarenco P, Kim JS, Labreuche J, Charles H, Abtan J, Bejot Y, et al. A comparison of two LDL cholesterol targets after ischemic stroke. *N. Engl. J. Med* 2020;**382**:9–19.
152. Grundy SM, Stone NJ, Bailey AL, Beam C, Birtcher KK, Blumenthal RS, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APHA/ASPC/NLA/PCNA guideline on the management of blood cholesterol: a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines. *Circulation* 2019;**139**:e1082–e1143.
153. Sagris D, Ntaios G, Georgiopoulos G, Kakaletsis N, Elisaf M, Katsiki N, et al. Recommendations for lipid modification in patients with ischemic stroke or transient ischemic attack: a clinical guide by the Hellenic Stroke Organization and the Hellenic Atherosclerosis Society. *Int. J. Stroke* 2021;**16**(6):738–750.
154. Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, et al. Cardiovascular risk reduction with icosapent ethyl for hypertriglyceridemia. *N Engl J Med* 2019;**380**:11–22.
155. Hagen PT, Scholz DG, Edwards WD. Incidence and size of patent foramen ovale during the first 10 decades of life: an autopsy study of 965 normal hearts. *Mayo Clin. Proc* 1984;**59**:17–20.
156. Messe SR, Gronseth G, Kent DM, Kizer JR, Homma S, Rosterman L, et al. Practice advisory: recurrent stroke with patent foramen ovale (update of practice parameter): report of the guideline development, dissemination, and implementation subcommittee of the American Academy of Neurology. *Neurology* 2016;**87**:815–821.
157. Saver JL, Mattle HP, Thaler D. Patent foramen ovale closure versus medical therapy for cryptogenic ischemic stroke: a topical review. *Stroke* 2018;**49**:1541–1548.
158. Merkler AE, Gialdini G, Yaghi S, Okin PM, Iadecola C, Navi BB, et al. Safety outcomes after percutaneous transcatheter closure of patent foramen ovale. *Stroke* 2017;**48**:3073–3077.
159. Chen JZ, Thijs VN. Atrial fibrillation following patent foramen ovale closure: systematic review and meta-analysis of observational studies and clinical trials. *Stroke* 2021;**52**:1653–1661.
160. Fisher M, Hill JA. Ischemic stroke mandates cross-disciplinary collaboration. *Stroke* 2018;**49**:273–274.
161. Hart RG, Catanese L, Perera KS, Ntaios G, Connolly SJ. Embolic stroke of undetermined source: a systematic review and clinical update. *Stroke* 2017;**48**:867–872.
162. Delewi R, Zijlstra F, Piek JJ. Left ventricular thrombus formation after acute myocardial infarction. *Heart* 2012;**98**:1743–1749.
163. Vaitkus PT, Barnathan ES. Embolic potential, prevention and management of mural thrombus complicating anterior myocardial infarction: a meta-analysis. *J Am Coll Cardiol* 1993;**22**:1004–1009.
164. Keren A, Goldberg S, Gottlieb S, Klein J, Schuger C, Medina A, et al. Natural history of left ventricular thrombi: their appearance and resolution in the posthospitalization period of acute myocardial infarction. *J Am Coll Cardiol* 1990;**15**:790–800.
165. Yaghi S, Liberman AL, Atalay M, Song C, Furie KL, Kamel H, et al. Cardiac magnetic resonance imaging: a new tool to identify cardioaortic sources in ischemic stroke. *J. Neurol Neurosurg Psychiatry* 2017;**88**:31–37.
166. Weinsaft JW, Kim HW, Crowley AL, Klem I, Shenoy C, Van Assche L, et al. LV thrombus detection by routine echocardiography: insights into performance

- characteristics using delayed enhancement CMR. *JACC Cardiovasc Imaging* 2011;**4**:702–712.
167. Takasugi J, Yamagami H, Noguchi T, Morita Y, Tanaka T, Okuno Y, et al. Detection of left ventricular thrombus by cardiac magnetic resonance in embolic stroke of undetermined source. *Stroke* 2017;**48**:2434–2440.
  168. Barbieri A, Mantovani F, Bursi F, Faggiano A, Boriani G, Faggiano P. Optimal use of echocardiography in management of thrombosis after anterior myocardial infarction. *Echocardiography* 2020;**37**:1287–1295.
  169. Fleddermann AM, Hayes CH, Magalski A, Main ML. Efficacy of direct acting oral anticoagulants in treatment of left ventricular thrombus. *Am J Cardiol* 2019;**124**:367–372.
  170. Tomasoni D, Sciatti E, Bonelli A, Vizzardì E, Metra M. Direct oral anticoagulants for the treatment of left ventricular thrombus—a new indication? A meta-summary of case reports. *J Cardiovasc Pharmacol* 2020;**75**:530–534.
  171. Ntaios G, Hart RG. Embolic stroke. *Circulation* 2017;**136**:2403–2405.
  172. Papanagiotou P, Ntaios G. Endovascular thrombectomy in acute ischemic stroke. *Circ Cardiovasc Interv* 2018;**11**:e005362.
  173. Schnabel RB, Haeusler KG, Healey JS, Freedman B, Boriani G, Brachmann J, et al. Searching for atrial fibrillation poststroke: a white paper of the af-screen international collaboration. *Circulation* 2019;**140**:1834–1850.
  174. Ntaios G. Embolic stroke of undetermined source: JACC review topic of the week. *J Am Col. Cardiol* 2020;**75**:333–340.
  175. Doehner W, Leistner DM, Audebert HJ, Scheitz JF. The role of cardiologists on the stroke unit. *Eur Heart J Suppl* 2020;**22**:M3–M12.
  176. Doehner W, Mazighi M, Hofmann BM, Lautsch D, Hindricks G, Bohula EA, et al. Cardiovascular care of patients with stroke and high risk of stroke: the need for interdisciplinary action: a consensus report from the European Society of Cardiology Cardiovascular Round Table. *Eur J Prev Cardiol* 2020;**27**:682–692.
  177. Harwell TS, Blades LL, Oser CS, Dietrich DW, Okon NJ, Rodriguez DV, et al. Perceived risk for developing stroke among older adults. *Prev Med* 2005;**41**:791–794.
  178. Hatano S. Experience from a multicentre stroke register: a preliminary report. *Bull World Health Organ* 1976;**54**:541–553.
  179. <https://www.Corhealthontario.ca/csbp-taking-action-resource-overview-en-22may13f.pdf>, accessed on 3/05/2021.
  180. Meretoja A, Acciarresi M, Akinyemi RO, Campbell B, Dowlatshahi D, English C, et al. Stroke doctors: who are we? A world stroke organization survey. *Int J Stroke* 2017;**12**:858–868.
  181. Tattisumak T. Implication of the recent positive endovascular intervention trials for organizing acute stroke care: European perspective. *Stroke* 2015;**46**:1468–1473.
  182. Nardai S, Lanzer P, Abelson M, Baumbach A, Doehner W, Hopkins LN, et al. Interdisciplinary management of acute ischaemic stroke: current evidence training requirements for endovascular stroke treatment. Position paper from the ESC council on stroke and the European association for percutaneous cardiovascular interventions with the support of the European board of neurointervention. *Eur Heart J* 2021;**42**:298–307.
  183. Ford GA, Hargroves D, Lowe D, Rooney G, Fisher R, Oatley H, Lough J. Restoration and recovery of stroke services during the covid-19 pandemic. 2020.
  184. Markus HS, Martins S. Covid-19 and stroke—understanding the relationship and adapting services. A global world stroke organisation perspective. *Int J stroke* 2021;**16**:241–247.
  185. Katsoularis I, Fonseca-Rodriguez O, Farrington P, Lindmark K, Fors Connolly AM. Risk of acute myocardial infarction and ischaemic stroke following covid-19 in Sweden: a self-controlled case series and matched cohort study. *Lancet* 2021;**398**:599–607.
  186. Douiri A, Muruet W, Bhalla A, James M, Paley L, Stanley K, et al. Stroke care in the United Kingdom during the covid-19 pandemic. *Stroke* 2021;**52**:2125–2133.
  187. Russell AL R, Hardwick M, Jayantham A, White LM, Deb S, Burnside G, et al. Spectrum, risk factors and outcomes of neurological and psychiatric complications of covid-19: a UK-wide cross-sectional surveillance study. *Brain Commun* 2021;**3**:fab168.
  188. Perry RJ, Smith CJ, Roffe C, Simister R, Narayanamoorthi S, Marigold R, et al. Characteristics and outcomes of COVID-19 associated stroke: a UK multicentre case-control study. *J Neurol Neurosurg Psychiatry* 2021;**92**:242–248.
  189. Qureshi AI, Baskett WI, Huang W, Shyu D, Myers D, Raju M, et al. Acute ischemic stroke and COVID-19: an analysis of 27 676 patients. *Stroke* 2021;**52**:905–912.
  190. July J, Pranata R. Impact of the coronavirus disease pandemic on the number of strokes and mechanical thrombectomies: a systematic review and meta-analysis. *J Stroke Cerebrovasc Dis* 2020;**29**:105185.
  191. Giebel C, Pulford D, Cooper C, Lord K, Shenton J, Cannon J, et al. COVID-19-related social support service closures and mental well-being in older adults and those affected by dementia: a UK longitudinal survey. *BMJ Open* 2021;**11**:e045889.
  192. Johnson W, Onuma O, Owolabi M, Sachdev S. Stroke: a global response is needed. *Bull World Health Organ* 2016;**94**:634–634A.
  193. O'Donnell MJ, Chin SL, Rangarajan S, Xavier D, Liu L, Zhang H, et al. Global and regional effects of potentially modifiable risk factors associated with acute stroke in 32 countries (INTERSTROKE): a case-control study. *Lancet* 2016;**388**:761–775.
  194. Feinstein MJ, Hsue PY, Benjamin LA, Bloomfield GS, Currier JS, Freiberg MS, et al. Characteristics, prevention, and management of cardiovascular disease in people living with HIV: a scientific statement from the American Heart Association. *Circulation* 2019;**140**:e98–e124.
  195. Cohen AJ, Brauer M, Burnett R, Anderson HR, Frostad J, Estep K, et al. Estimates and 25-year trends of the global burden of disease attributable to ambient air pollution: an analysis of data from the global burden of diseases study 2015. *Lancet* 2017;**389**:1907–1918.
  196. Pandian JD, Kalkonde Y, Sebastian IA, Felix C, Urimubenshi G, Bosch J. Stroke systems of care in low-income and middle-income countries: challenges and opportunities. *Lancet* 2020;**396**:1443–1451.
  197. Lavados PM, Hoffmeister L, Moraga AM, Vejar A, Vidal C, Gajardo C, et al. Incidence, risk factors, prognosis, and health-related quality of life after stroke in a low-resource community in Chile (NANDU): a prospective population-based study. *Lancet Glob Health* 2021;**9**:e340–e351.
  198. Sposato LA, Lam M, Allen B, Shariff SZ, Saposnik G. First-ever ischemic stroke and incident major adverse cardiovascular events in 93 627 older women and men. *Stroke* 2020;**51**:387–394.
  199. Prosser J, MacGregor L, Lees KR, Diener H-C, Hacke W, Davis S. Predictors of early cardiac morbidity and mortality after ischemic stroke. *Stroke* 2007;**38**:2295–2302.
  200. Yoshimura S, Toyoda K, Ohara T, Nagasawa H, Ohtani N, Kuwashiro T, et al. Takotsubo cardiomyopathy in acute ischemic stroke. *Annals of Neurology* 2008;**64**:547–554.
  201. Ghadri JR, Cammann VL, Napp LC, Jurisic S, Diekmann J, Bataiosu DR, et al. Differences in the clinical profile and outcomes of typical and atypical Takotsubo syndrome: data from the International Takotsubo Registry. *JAMA Cardiology* 2016;**1**:335–340.
  202. Kallmünzer B, Breuer L, Kahl N, Bobinger T, Raaz-Schrauder D, Huttner HB, et al. Serious cardiac arrhythmias after stroke. *Stroke* 2012;**43**:2892–2897.
  203. Lian H, Xu X, Shen X, Chen J, Mao D, Zhao Y, et al. Early prediction of cerebral-cardiac syndrome after ischemic stroke: the Panscan scale. *BMC Neurology* 2020;**20**:272.
  204. Samuels MA. The brain-heart connection. *Circulation* 2007;**116**:77–84.
  205. Scheitz JF, Nolte CH, Doehner W, Hachinski V, Endres M. Stroke–heart syndrome: clinical presentation and underlying mechanisms. *Lancet Neurol* 2018;**17**:1109–1120.
  206. Barugh AJ, Gray P, Shenkin SD, MacLulich AMJ, Mead GE. Cortisol levels and the severity and outcomes of acute stroke: a systematic review. *J Neurol* 2014;**261**:533–545.
  207. Dickens AM, Tovar-y-Romo LB, Yoo S-W, Trout AL, Bae M, Kanmogne M, et al. Astrocyte-shed extracellular vesicles regulate the peripheral leukocyte response to inflammatory brain lesions. *Sci Signal* 2017;**10**:eaai7696.
  208. Gauberti M, Montagne A, Quenault A, Vivien D. Molecular magnetic resonance imaging of brain-immune interactions. *Front Cell Neurosci* 2014;**8**:389.
  209. Scheitz JF, Mochmann H-C, Erdur H, Tütüncü S, Haeusler KG, Grittner U, et al. Prognostic relevance of cardiac troponin t levels and their dynamic changes measured with a high-sensitivity assay in acute ischaemic stroke: analyses from the trelas cohort. *Int J Cardiol* 2014;**177**:886–893.
  210. Li L, Yiin GS, Geraghty OC, Schulz UG, Kuker W, Mehta Z, et al. Incidence, outcome, risk factors, and long-term prognosis of cryptogenic transient ischaemic attack and ischaemic stroke: a population-based study. *Lancet Neurol* 2015;**14**:903–913.
  211. Burton CA C, Murray J, Holmes J, Astin F, Greenwood D, Knapp P. Frequency of anxiety after stroke: a systematic review and meta-analysis of observational studies. *Int J Stroke* 2013;**8**:545–559.
  212. Hackett ML, Pickles K. Part I: frequency of depression after stroke: an updated systematic review and meta-analysis of observational studies. *Int J Stroke* 2014;**9**:1017–1025.
  213. Medeiros GC, Roy D, Kontos N, Beach SR. Post-stroke depression: a 2020 updated review. *Gen Hosp Psychiatry* 2020;**66**:70–80.
  214. Rafsten L, Danielsson A, Sunnerhagen KS. Anxiety after stroke: a systematic review and meta-analysis. *J Rehabil Med* 2018;**50**:769–778.
  215. Robinson RG, Jorge RE. Post-stroke depression: a review. *Am J Psychiatry* 2016;**173**:221–231.
  216. Beauchamp A, Peeters A, Tonkin A, Turrell G. Best practice for prevention and treatment of cardiovascular disease through an equity lens: a review. *Eur J Cardiovasc Prev Rehabil* 2010;**17**:599–606.
  217. Schultz WM, Kelli HM, Lisko JC, Varghese T, Shen J, Sandesara P, et al. Socioeconomic status and cardiovascular outcomes: challenges and interventions. *Circulation* 2018;**137**:2166–2178.
  218. Boehme C, Toell T, Lang W, Knoflach M, Kiechl S. Longer term patient management following stroke: a systematic review. *Int J Stroke* 2021;**16**:917–926.